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Abstract 
Introduction 
The incidence of oesophageal adenocarcinoma is increasing significantly with 
Scotland having the highest rates in Western Europe. Despite this oesophageal 
cancer continues to be a late presenting malignancy with treatment options 
limited to palliative therapy in up to 80% of cases. The identification of patients 
with Barrett's High Grade Dysplasia (HGD) or early oesophageal cancer therefore 
remains a priority.  
 
Such patients with HGD in Barrett's oesophagus or early carcinoma often have 
medical co-morbidity precluding them from radical therapy in the form of 
surgical resection or chemoradiotherapy. The development of less invasive 
endoscopic therapy to treat such superficial disease is also therefore a priority. 
Endoscopic therapies have been shown to be safe with minimal morbidity and 
mortality and as an alternative potentially curative therapy in early malignant 
disease and satisfactory palliation in locally advanced disease of the oesophagus. 
The optimal endoscopic treatment for HGD and early cancer however is not yet 
fully established. 
 
Photodynamic therapy (PDT) is a new evolving treatment involving 
administration of a photosensitiser with subsequent endoscopic activation with 
laser light to treat pre-malignant and malignant disease of the oesophagus. 
 
 Aim 
This thesis aims to explore the role of PDT in the treatment of neoplastic disease 
of the oesophagus. 
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Patients  
Between 1999 and 2011, three patient populations have been assessed: 
1) HGD Barrett's oesophagus, 2) early T1 oesophageal cancer and 3) locally 
advanced inoperable oesophageal cancer. 
 
1) Twenty one patients with HGD in Barrett's oesophagus, 16 male and median 
age 70 years who were unfit for oesophagectomy due to medical co-morbidity 
were treated with PDT.  
  
2) Thirty eight patients, 21 male median age 72 years were treated with PDT 
with curative intent for early T1 oesophageal carcinoma in this surgical unit. 
These patients were staged with a combination of endoscopy, CT and EUS and 
were unsuitable for radical treatment due to co-morbidity.  
 
3) Twenty five patients with locally advanced oesophageal cancer with or 
without metastases, 16 male, median age 79 years were treated with PDT as a 
palliative therapy for dysphagia. A second group of 25 patients previously 
treated with self expanding metal stents (SEMS) between 1998 and 2000 were 
used as a comparative group. 
Methods 
All patients were discussed at the regional MDT and were given visual and 
written information regarding PDT. All patients were treated as inpatients and 
received porfimer sodium IV at 2mg/kg bodyweight with laser light activation at 
630nm 48 hours later. The laser light dose for HGD patients was 100-200J/cm 
and 300J/cm for early cancer and palliation. Patients remained on long term 
high dose proton pump inhibitor post procedure. Patients returned at 6 to 12 
4 
weekly intervals for repeat endoscopy and biopsy in the HGD and early cancer 
cohorts. 
Data has been collated prospectively for patients with HGD and early cancer and 
both retrospectively and prospectively for the palliative patients. 
CRP levels pre and post- PDT in the early cancer cohort were evaluated to 
investigate the inflammatory response after PDT. 
Results 
Patients treated with PDT for HGD in Barrett's oesophagus had a median follow 
up of 62 months (2-114 months). Overall twenty of 21 patients were assessed 
(one died of a non procedure related cause 3 weeks post PDT). Patients had a 
median number of 1.5 PDT sessions (range 1-2).Overall 17/20 (85%) patients 
remained free of HGD at a median follow up of 5 years. Three patients 
developed adenocarcinoma at 47, 48 and 54 months giving a cancer progression 
rate of 15%. During the treatment period 4/20 developed recurrence of HGD but 
are now dysplasia free after repeat PDT (three patients) and radiofrequency 
ablation (RFA) (one patient). There was a significant reduction in length of 
Barrett's segment pre and post- PDT from median 5 to 3cm (range 0-12cm) 
p=0.035 respectively. 
 
Patients with early oesophageal cancer had a median follow up of 40 months (1 
to 123 months). All patients were staged as T0N0 or T1N0. Twenty six out of 38 
(68%) had a complete endoscopic and histological response to treatment 6-8 
weeks post- PDT. Overall 50% developed recurrent carcinoma at a median of 8 
months. The remaining 50% of patients with initial complete response remain 
disease free or were disease free until time of death. One third of patients died 
of non oesophageal cancer related causes.  
5 
PDT induced a systemic inflammatory response with a median rise in CRP of 
466%. Patients with a baseline CRP<10mgl-1 had a significantly increased length 
of survival compared to those with a CRP>10mgl-1. 
 
As a palliative therapy PDT had no effect on quality of life despite significant 
improvement in dysphagia. Such patients however having PDT had improved 
survival compared to those having self expanding metal stents (SEMS): 132.5 vs 
105 days respectively. In health economics terms the cost per day survival 
however was similar for PDT and SEMS. 
Conclusion 
Photodynamic therapy successfully ablates HGD in Barrett's oesophagus and may 
be used with curative intent in early cancer for those patients who have no 
alternative radical option. PDT improves survival in patients with locally 
advanced oesophageal cancer compared to SEMS with no alteration in quality of 
life and similar costs. The survival benefit may be secondary to immune 
modulation by PDT rather than through a systemic inflammatory response effect. 
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Preface 
Photodynamic therapy involves the administration of a photosensitiser which is 
preferentially taken up by macrophages which are found in high concentrations 
in malignant tissue, resulting targeting of malignant cells. The photosensitiser is 
activated by laser light creating an oxidative reaction producing cytotoxic 
oxygenated molecules. Macrophages also release inflammatory and immune 
mediators once the accumulated photosensitiser is activated. In the oesophagus 
laser light is applied directly at endoscopy to the oesophagus creating an c 
ablative therapy which allows treatment of pre-malignant and malignant disease 
of the oesophagus. 
 
Oesophageal cancer is increasing in incidence in the western world and with an 
ageing population many patients are not fit in terms of co-morbidity or 
performance status for either major surgical resection or radical 
chemoradiation. Endoscopic therapies may therefore allow oesophageal cancer 
to be treated locally with less morbidity and mortality than surgery and be an 
important option in the range of oesophageal cancer therapy. 
 
This thesis explores the current role of photodynamic therapy in the treatment 
of neoplastic disease of the oesophagus. 
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1 Oesophageal Cancer  
Oesophageal cancer is a disease which commonly presents late in an elderly 
population with about 80% of patients suitable for palliative treatment only. 
There are two main types of oesophageal cancer: adenocarcinoma (AC) and 
squamous cell carcinoma (SCC), though rarer types do exist (leiomyosarcoma, 
non small cell).Three quarters of adenocarcinomas occur in the distal 
oesophagus with SCC more evenly distributed between the upper and middle 
third. 
 
1.1 Incidence of all types of oesophageal cancer 
Oesophageal cancer is the ninth commonest cancer in the UK accounting for 
2.6% of all UK cancer(1) and the eighth most common cancer worldwide(2). 
Worldwide each year 462,000 people are diagnosed with oesophageal cancer and 
386,000 people die from it. The majority of cases – 85% -  are diagnosed in 
developing countries where most cases are SCC and it is the 4th most common 
cancer in men(2)(Figure 1).  
Figure 1: World age-standardised incidence rates for oesophageal cancer, 2002 
estimates  
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The highest risk areas worldwide are in the oesophageal cancer belt extending 
from northern Iran through the central Asian republics to north-central China(2). 
China has the highest incidence worldwide with age standardised rates per 
100,000 being 184 for men and 123 for women compared to 14.4 and 5.5 in the 
UK(3). However there is a wide variation in incidence between individual 
countries and ethnic groups within a single population. In the USA SCC is six 
times higher in black than white men but AC is four times higher in white than 
black men(4).Worldwide the incidence rate of AC of the oesophagus is increasing 
in both sexes particularly in USA, Canada, South Australia, Scotland, Denmark, 
Iceland, Finland, Norway and Sweden where as the rates of SCC are stable or 
decreasing(5). In Europe alone, French men have the highest rates of AC just 
above the UK (Figure 2)(5). 
Figure 2: Age-standardised (European) incidence rates, oesophageal cancer, EU 
countries, 2002 estimates 
  
The incidence of oesophageal cancer has been on the increase over the last 30 
years in the UK. This is mainly in AC with the incidence of SCC being static. In 
men the overall incidence of oesophageal cancer has risen by 50% in the past 25 
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years(6). Recent figures published by Cancer Research UK have shown the 
number of cases diagnosed was around 9.6 per 100,000 men in 1983 and 14.4 per 
100,000 in 2007(6). The most dramatic rise was noted among men in their 50s, 
among whom the incidence has risen by 67% (6). In women the incidence rose 
only by 8% from 5.1 to 5.5 per 100,000 (6). This trend is also mirrored in 
Scotland. Scotland has a higher incidence of oesophageal cancer than the rest of 
the UK (7). The Scottish government cancer incidence projections for 2001 to 
2020 reveals a 64% increase in oesophageal cancer in Scotland with 3,907 
patients diagnosed between 1996 and 2000 and a further predicted 6,420 cases 
between 2016 and 2020(8). In Scotland oesophageal cancer is the fifth most 
common cancer in males and 13th most common cancer in females, accounting 
for 4% and 1.9% of all cancer respectively. 
 
1.2 Mortality 
In 2008 7,606 people died of oesophageal cancer in the UK. The numbers of 
oesophageal cancer deaths and distribution in terms of sex and age are very 
similar to those of the incidence due to its poor prognosis. In the UK oesophageal 
cancer is responsible for about 5% of all cancer deaths making it the sixth most 
common cause of cancer death overall, 4th in men and 6th in women(6). 
 
1.3 Survival 
Oesophageal cancer tends to have poor survival rates due to late presentation, 
advanced stage at diagnosis with many elderly patients having severe co-existing 
medical conditions limiting optimal treatment. Survival from oesophageal cancer 
is clearly stage related and decreases with increasing stage as illustrated in 
Graph 1(9).  
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Graph 1 Oesophageal cancer survival according to stage 
 
 
 
Survival from oesophageal cancer has however improved over the last 20 years. 
The most recent analysis of survival in Scotland was the Scottish Audit of Gastric 
and Oesophageal Cancer Report 1997-2000(10). Without surgery patients had a 1 
and 2 year survival of 32% and 17% respectively. With resectional surgery this 
increased to 53.9% and 32.8% survival at 1 and 2 years. More recently a Swedish 
group assessed survival after surgery for oesophageal cancer and also showed an 
improvement from 1987 to 2000(11). They noted respective 1,3 and 5 year 
survival rates in 1987 of 46.5%,24.1% and 19.7% (11) with further  improvement 
in 2000 to 61.7%, 39.9% and 30.7% (11). These results were noted for primary 
resection alone. This could be explained by improved patient staging and 
selection for surgery, better surgical technique and improved critical care 
facilities. The introduction of neo-adjuvant chemotherapy to most patients in 
the UK has further improved survival with 5 year survival rates of 23% compared 
to 17% for surgery alone (long term results of MRC OEO2 randomised trial)(12). 
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1.4 Aetiology 
In the UK in 2007 7,966 people diagnosed with oesophageal cancer had a male: 
female ratio of nearly 2:1.However the male: female ratio for AC is higher, 
about 5-10 fold making it one of the highest sex differentials of non occupational 
cancers(13). The lifetime risk of developing oesophageal cancer is 1 in 64 for 
men and 1 in 116 for women in the UK (these figures are based on incidence and 
mortality figures for 2001-2005(1)).It is unclear why there is a difference in male 
and female development of oesophageal cancer. There are several possible 
mechanisms.  
There may be protective effects of female reproductive hormones such as 
oestrogen and progesterone(14) but evidence for this remains inconclusive. 
Supporting this theory is a population based study (15) suggesting an increased 
incidence of oesophageal cancer in females post menopausally, however a 
further study (16) has shown no difference in incidence with women treated with 
HRT which would be expected to be protective.  
There is different iron storage in men and women and iron has been shown to be 
involved in many inflammatory and carcinogenic pathways(17;18). It is not yet 
clear what role biologically active iron plays in the development of oesophageal 
AC.  
 
There are non endogenous risk factors for both types of oesophageal cancer such 
as Gastro-oesophageal reflux disease (GORD) but prevalence of this is similar in 
both sexes. There are lifestyle factors such as diet, alcohol and smoking. 
Smoking has been shown not to account for the difference(19) and research 
continues to determine if other lifestyle factors have a role to play.  
There is a definite positive association between social deprivation and 
development of oesophageal cancer but this differs depending on histology.  
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1.4.1 Squamous Cell Carcinoma 
Analysis of Scottish data shows a clear association between SCC  social 
deprivation but very little difference for AC(10) (20).Smoking is associated with 
increased risk for both SCC and AC (21;22).It has been shown that the ingestion 
of tobacco condensates brings about carcinogens particularly nitrosamines, in 
contact with the oesophageal mucosa(23). The risk of oesophageal cancer 
correlates directly with the quantity of cigarettes smoked per day and the 
duration of smoking (21;22). 
 
1.4.2 Adenocarcinoma (AC) 
Adenocarcinoma is associated with GORD. People with GORD have an eight fold 
increase in the risk of oesophageal carcinoma(24). Other markers of GORD such 
as hiatus hernia, oesophageal ulcer and frequent use of antacids or H2 
antagonists are also associated with an increased risk but are not independent 
risk factors(25). Alcohol consumption is a risk factor and alcohol and smoking are 
both associated with decreasing the lower oesophageal sphincter pressure hence 
predisposing to gastroesophageal reflux(26).Drugs which relax the 
gastroesophageal sphincter and increase reflux such as anticholinergics, 
aminophyllines and beta-blockers may also contribute to the development of 
these cancers(27). Dietary nitrate is thought to be mutagenic at the oesophago-
gastric junction (OGJ) and oesophagus. Dietary nitrate (25%) is absorbed and 
then re-secreted in saliva, of which 30% is then converted by buccal bacteria to 
nitrite. When this is swallowed gastric acid converts this to nitric oxide. This has 
been shown to be maximal at the oesophago-gastric junction and cardia 
suggesting this high concentration may contribute to neoplasia at this site(28). In 
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patients with reflux then there is in-situ formation of nitric oxide causing 
nitrosative stress directly in the oesophagus which may lead to 
carcinogenesis(29). There is an increased prevalence of obesity in the western 
world and this is thought to add to the rising incidence of oesophageal AC by 
increasing intra-abdominal pressure and hence GORD(30).In fact several 
epidemiologic studies have shown a 3 to 6 fold excess risk amongst overweight 
individuals(30;31). 
 
1.5 Barrett’s Oesophagus 
Barrett’s oesophagus is the replacement of normal stratified squamous 
epithelium with specialised columnar epithelium similar to that in the small 
intestine, described as intestinal metaplasia. This intestinal metaplasia can 
become dysplastic with time, leading to low grade dysplasia then high grade 
dysplasia and onto AC (32;33).Endoscopically Barrett’s oesophagus is seen as 
salmon pink tongues of mucosa extending from the gastroesophageal junction to 
meet the normal pale oesophageal squamous mucosa (Figure 3). 
Figure 3 Barrett's Oesophagus 
          
Circumferential Barrett's oesophagus with visible tongues 
 
 Up to 15% of percent of patients with GORD develop Barrett’s oesophagus (34-
37). Barrett’s may also develop in patients with no symptoms of GORD(38).  
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Barrett’s oesophagus is a pre-malignant condition with an annual neoplastic 
transformation rate of 0.5-1% (39;40). Patients with Barrett’s oesophagus have a 
30-125 fold increased risk of developing AC compared to the general population. 
For this reason the majority of patients diagnosed with Barrett’s oesophagus are 
now in local surveillance programmes with endoscopy and biopsy every 2 years 
depending on histology (41;42).  
 
It is difficult to diagnose dysplasia within a Barrett's segment on standard white 
light endoscopy therefore currently the Seattle protocol(43) is used in most units 
with the Barrett's segment biopsied in 4 quadrants every 2cm throughout its 
length. Newer imaging modalities are now available which may improve the 
diagnosis of dysplasia and therefore detect pre-malignant changes earlier such 
as narrow band imaging (NBI), chromoendoscopy and autofluorescence (AF).  
 
1.5.1 Narrow band imaging 
NBI is a high resolution technique that enhances the detail of the mucosal 
surface without the use of dyes. It has been shown in a meta-analysis(44) of 8 
studies of 446 patients and 2194 lesions to have a pooled sensitivity and 
specificity for detecting Barrett's oesophagus of 95% and 65% respectively. The 
pooled sensitivity and specificity for detection of HGD was 96% and 94% 
respectively which suggests that NBI may be useful in the detection of both 
Barrett's and HGD.  
 
1.5.2 Chromoendoscopy 
Chromoendoscopy involves topical application of stains to improve tissue 
localisation, characterisation and diagnosis at endoscopy. Stains are injected 
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through a catheter via the biopsy channel onto the mucosa. Common stains used 
are Lugol's solution, methylene blue, acetic acid and indigo carmine, all of which 
are readily available in most hospitals. This makes chromoendoscopy more 
widely available, simple and inexpensive to perform. There is limited evidence 
however of the benefit for chromoendoscopy in Barrett's oesophagus as this has 
been more readily used in the colon. There also appears to be a large amount of 
inter-observer error with no standardised classification of oesophageal 
appearances.  
 
1.5.3 Autofluorescence 
AF endoscopy works on the principle that some of the endoscopic light is 
reflected, some is absorbed and some transforms mucosal molecules into an 
excited state via a light-tissue reaction resulting in a change in reflected 
wavelength (known as autofluorescence). The autofluorescence of normal 
metaplastic and dysplastic tissue all differ. The AF endoscope allows real time 
assessment of the oesophagus with the ability to switch to and from white and 
AF light. This then allows more targeted biopsy of areas suggestive of dysplasia, 
however trials to date have not shown an improvement in dysplasia diagnosis 
using AF compared to either standard endoscopy or methylene blue 
chromoendoscopy (45-47). 
 
1.5.4 Barrett's Surveillance 
A large number of patients diagnosed with Barrett’s are currently in surveillance 
programmes locally which allows clinicians a unique opportunity to detect high 
grade dysplasia (HGD) in Barrett’s oesophagus or early carcinoma limited to the 
oesophageal mucosa. This allows the potential for curative endoscopic therapy 
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whilst preserving the integrity of the oesophagus. Whether endoscopic 
surveillance really does detect early disease and lead to reduced mortality is 
currently under investigation with the BOSS (Barrett’s Oesophagus Surveillance 
Study) trial(48). 
 
Although one Swedish study has estimated the prevalence of Barrett's in the 
population to be 1.6%(49) the true incidence and prevalence is unknown. 
Unfortunately 5% of patients with Barrett’s are never diagnosed, with a silent 
majority of patients with Barrett’s oesophagus remaining unrecognised. 
Therefore the majority of oesophageal cancers still present de-novo (50-52). 
 
1.6 Oesophageal cancer 
1.6.1 Diagnosis 
The majority of oesophageal cancers are diagnosed with an endoscopy which 
allows direct visualisation of the lesion and biopsy to obtain histological 
confirmation of cancer. Occasionally patients may have a barium meal or CT 
suggesting the diagnosis first but endoscopy is always the next investigation to 
achieve a tissue diagnosis. 
 
1.6.2 Staging Investigations 
Staging is important in all cancers to determine treatment strategy and 
prognosis.  In oesophageal cancer accurate staging is particularly important 
when considering endoscopic therapy as depth of invasion and lymph node 
involvement will determine if endoscopic therapy is appropriate. If a tumour is 
limited to the mucosa with no penetration of the muscularis mucosa then the 
risk of lymph node metastases is low (0-2%), whereas once the submucosa is 
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breached this risk increases to at least 25% (53;54) and this will affect survival. 
The risks of lymph node metastases in early oesophageal cancer has recently 
been extensively studied with lymph node metastases occurring more frequently 
in SCC compared to AC (54-61) (see table 1). 
Table 1 Likelihood of lymph node invasion according to penetration depth(62) 
 
Invasion  Chance of lymph node metastases (%) 
 Adenocarcinoma(54-57)  Squamous cell carcinoma (58-61) 
Mucosal M1 (epithelium) 0 0 
M2 (lamina propria) 0 0–6 
M3 (muscularis mucosa) 0–12 4–18 
Submucosal SM1 (upper third) 0–21 11–53 
SM2 (middle third) 23–36 22–54 
SM3 (lower third) 36–69 40–61 
 
 Endoscopic therapy can only be curative where the neoplasm is mucosal (M1-3). 
Endoscopic treatment of superficial sub-mucosal (sm1) cancers remains 
controversial. 
 
1.6.2.1 Endoscopic Mucosal Resection (EMR) 
This involves resection of an endoscopically visible lesion or nodule with a 
specimen for histological evaluation at the end of the procedure. The specimen 
then gives important information on histology, resection margin clearance and 
depth of invasion. EMR has also been shown to improve diagnostic consistency 
with upgrading of pathology in 40% cases(63). EMR involves local snare excision 
of target lesion with a suction cap(64) or band ligation(65). 
 
1.6.2.2 CT 
As previously stated prognosis is closely determined by stage. Once a patient has 
a confirmed oesophageal carcinoma staging investigations are carried out. This is 
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initially a CT chest, abdomen and pelvis to assess distant disease and nodal 
status. However CT is not particularly accurate at assessing loco-regional 
disease, poorly detects coeliac lymph node metastases(66) and does not 
accurately assess depth of invasion (T stage). In fact is has been shown that CT 
reports local tumour T staging correctly in only 42% of cases(67). Improved spiral 
CT however may lead to significant improvements in staging in the near future. 
 
1.6.2.3 Endoscopic Ultrasound (EUS) 
 Endoscopic Ultrasound (EUS) is now the standard investigation to assess loco-
regional disease if a tumour appears operable. EUS is accurate for T staging in 
89% of cases in a meta-analysis(68) though this is less for tumours >5cm, stenotic 
tumours, those at the OGJ and superficial cancers(69). 
 
EUS has been involved in the initial staging process of early cancers being 
considered for endoscopic therapy.  It has previously been demonstrated that 
EUS is important in patient selection for those that will benefit from PDT for 
early cancer(70) however recent data has shown EUS has little to add to expert 
endoscopic assessment and a recent meta-analysis has revealed an accuracy of 
only 65% for EUS(69;71) for early cancers. Early oesophageal cancer staging 
currently involves initial endoscopic assessment with or without staging EMR 
rather than EUS, with CT and CTPET for more advanced lesions. 
 
 The main current role of EUS is to allow fine needle aspiration (FNA) of any 
suspicious nodes seen at the time or on CT to help determine suitability for 
radical treatment.  
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1.6.2.4 PET-CT 
PET-CT scans are more sensitive and specific at picking up metastatic 
disease(72-74) and the PET-CT scan will change management in about 20% of 
patients(i.e. avoid unnecessary surgery)(75). 
 
1.6.2.5 Laparoscopy 
In the fit patient with localised oesophageal AC (T1-T3) with no distant nodal or 
metastatic involvement who is being considered for surgery, the final staging 
process is a diagnostic laparoscopy. CT does not accurately assess the 
peritoneum. Laparoscopy is therefore to detect any missed peritoneal disease 
either macroscopically or microscopically on peritoneal cytology (76;77). Staging 
laparoscopy is only indicated in oesophageal SCC in lower third lesions which 
appear to have intra-abdominal involvement. 
 
1.6.3 Staging Classification 
The TNM 7 (tumour, node, metastases)  classification is used to describe tumour 
depth invasion (T0-T1(m1-m3 or sm 1)T2/3/4), nodal involvement N1-3, and 
metastatic involvement M0-M1(78) (Figure 4). 
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Figure 4 Oesophageal Cancer TNM Staging 
(78) 
 
 
 The major change to TNM classification between 2002 and 2010 was the 
development of a classification for SCC and AC separately. This developed from 
a worldwide survey of 4627 patients with oesophageal cancer who underwent 
surgery alone with lymph node negative tumour where prognosis was shown to 
be dependent on T stage as well as histology, grade and tumour location(79).  
 
 
Once the tumour stage has been decided then treatment options are discussed 
at the MDT. 
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1.7 Curative Therapy 
1.7.1 Premalignant or Early Cancer (HGD, T1m1-3 or sm1) 
1.7.1.1 Endoscopic Therapy 
 
As alluded to earlier, some groups feel that surgical resection is a step too far 
for pre-cancer (HGD) in Barrett’s oesophagus which is essentially a mucosal 
disease and even early T1N0 tumours (T1m1-3). The most appropriate treatment 
for oesophageal cancer staged as T1sm1 remains controversial. The concept of 
mucosal involvement only has led to the development of endoscopic procedures 
to treat and cure early oesophageal cancer. Development of endomucosal 
resection (EMR) and mucosal ablative techniques such as argon plasma 
coagulation, photodynamic therapy and radiofrequency ablation (initially used 
for patients unfit for radical therapies) are now being offered in some centres as 
an alternative to surgery in all patients.  
1.7.1.1.1 Argon Plasma Coagulation (APC) 
 
APC has been used for treating non dysplastic and dysplastic Barrett's 
oesophagus. Two randomised trials have compared APC to 5-Aminolevulinic acid 
(5ALA) induced PDT for non dysplastic Barrett's (80;81). Both APC alone or in 
combination with 5ALA ablated Barrett's oesophagus and led to complete 
reversal of Barrett's with repeated treatments as well as reducing the overall 
length of the Barrett's segment. APC was found to be superior to 5ALA with 97% 
vs 50% ablation at a median of 12 months respectively(80). Both trials had short 
term follow up therefore the incidence of cancer progression was unknown. A 
further randomised trial investigated the effect of APC on dysplastic Barrett's (23 
LGD patients and 3 HGD patients) (82). In this study Photofrin PDT was also used 
and PDT was superior to APC in eradicating  dysplasia 77% vs 67% at 12 months 
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respectively (82). A further study with larger numbers (29 patients with HGD) 
and longer term follow up of median 37months, studied the use of APC in  
Barrett's HGD in patients who were unfit or did not wish surgery(83). Eighty six 
percent of patients responded to the treatment (25/29) with twenty two 
patients having complete regression to neo-squamous oesophageal mucosa. Four 
patients developed adenocarcinoma of which 3 continued with APC as 
treatment(83). This showed APC is both a safe and effective treatment for HGD 
in Barrett's oesophagus. 
1.7.1.1.2 Endoscopic Mucosal Resection (EMR) 
 
EMR has been used as a solitary treatment(84;85) and also in combination with 
RFA(86). It has been shown to be effective in controlling disease in patients with 
HGD and early invasive cancer in the UK(84) with a cancer specific survival of 
93% at a median of 53 months. EMR alone used as a curative therapy with radical 
stepwise resection of the HGD/intramucosal cancer and the non-dysplastic 
Barrett's has a comparable high rate of complete histological response for 
neoplasia( 100% vs 96%) to focal EMR in combination with RFA(86). The problem 
with extensive EMR of the entire Barrett's segment and malignant lesion is the 
high complication rate with stricture formation between 43% - 88% (85;86) and 
the high number of re-intervention rates secondary to this. 
1.7.1.1.3 Radiofrequency Ablation (RFA) 
 
RFA has been shown to be a safe and effective treatment of HGD. In conjunction 
with focal EMR it is also effective in treating early oesophageal AC (87-89) and 
more recently early SCC (90). RFA has also been shown to increase disease-
specific-health-related quality of life(91) and have durability of eradication of 
dysplasia in >85% patients at 3 years with no maintenance RFA(92).Longer term 
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data on RFA is awaited. Early costing analysis suggests EMR and RFA are more 
cost effective than oesophagectomy for early lesions particularly in the high risk 
patient(93).  
 
 As the evidence for endoscopic therapy mounts, clinical practice is shifting and 
endoscopic therapy is being offered in some specialist centres as a primary 
treatment for all patients with HGD or early cancer of the oesophagus. 
 
1.7.2  Localised Oesophageal Cancer (T1sm2-3 and T2/3 N1) 
1.7.2.1 Surgery 
 
Surgery is still considered the gold standard in terms of a curative treatment for 
localised oesophageal cancer. Surgery is either by a transhiatal approach with a 
laparotomy and gastric mobilisation, blunt dissection in the chest and a left neck 
dissection to allow anastomosis onto the cervical oesophagus. The alternative is 
a two stage Ivor Lewis procedure whereby there is a laparotomy and gastric 
mobilisation followed by right thoracotomy, mobilisation of the intra-thoracic 
oesophagus and an anastomosis in the right chest.  
 
 Surgery is associated with high morbidity and mortality although this has 
improved over the years. Postoperative mortality in high volume centres with 
greater subspecialisation is now <5% (94)but morbidity remains high (20-30%) 
(95;96). Pneumonia (10%), cardiac arrhythmia(16%) and anastomotic leak(12%) 
are the commonest complications(97) with up to 25% of patients undergoing 
oesophagectomy having a postoperative pulmonary complication(98). The 
magnitude of surgery means there are some patients with early localised disease 
who have no surgical option due to their cardiorespiratory co-morbidity. There  
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are also patients who have mucosal disease only, in whom many feel a less 
radical, safer but sufficient alternative may be endoscopic therapy(99). 
 
There are no randomised trials comparing surgery and endoscopic therapies. One 
centre has retrospectively compared results for patients having oesophagectomy 
(n=38) and EMR with APC for HGD in Barrett's oesophagus (n=76)(100). Patients 
were matched for age, gender, infiltration depth, grade and follow up. Overall 
there was 100% complete remission in the surgical group and 98.7% in the 
endoscopic therapy group. During a 4 year follow up period one patient in the 
endoscopic group developed recurrence and 4 had metachronous tumours. There 
were no recurrences in the surgical group. Major complications occurred in 32% 
patients in the surgical group with none in the endoscopic group. Ninety day 
mortality was 2.6% for the surgical group and 0% for the endoscopic group. 
Interestingly all the surgical resections were node negative despite 19/38 being 
T1sm 2-3(100) which should have a high rate of lymph node invasion(101). 
  
1.7.2.2 Neoadjuvant Therapy 
 
The majority of patients in the UK now have neoadjuvant chemotherapy prior to 
radical oesophagectomy. OEO2 was a randomised controlled trial demonstrating 
an overall survival benefit with 2 cycles of cisplatin and fluorouracil followed by 
surgery compared to surgery alone(12). As well as 5 year survival benefit of 23% 
with chemotherapy compared to 17% with surgery alone OEO2 showed a reduced 
rate of incomplete (R2) resections and a reduced rate of tumour inoperability at 
the time of surgery with 14.3% inoperable in the chemotherapy group compared 
to 26.4% in the surgery alone group(12). This was consistent for both AC and 
SCC. 
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There is also an established benefit of chemoradiotherapy described in a 
randomised trial comparing neoadjuvent chemotherapy with neoadjuvant 
chemoradiotherapy(102). This trial however was closed early due to poor accrual 
but there were more complete pathologic responses in the chemoradiotherapy 
(17%) compared to chemotherapy (2.5%) groups. This was also associated with 
prolonged 3 year survival of 43% vs 27% in the chemoradiotherapy group 
compared to chemotherapy group. The main adverse event however was the 
associated higher surgical mortality of 10.2% post chemoradiotherapy compared 
to 3.8% with chemotherapy(102).Such high complication rates following surgery 
has limited this treatment combination to date. 
 
1.7.2.3 Chemoradiotherapy 
 
Chemoradiotherapy has been used alone and in conjunction with surgery. There 
are two randomised trials comparing the above which have failed to show 
improved survival with either although have shown improved loco-regional 
control and decreased need for palliative therapies when surgery is 
combined(103;104). A further trial comparing neoadjuvant chemoradiotherapy 
and surgery to surgery alone for oesophageal adenocarcinoma revealed a survival 
advantage of 32% vs. 6% at 3 years p=0.01 thereby favouring multimodal 
therapy(105). Post- operative morbidity in the two groups was very similar in 
terms of respiratory complications, leaks and chylothorax, however mortality 
was higher in the multimodal group 8.6% vs. 3.6%(105). It is this increased 
mortality in surgical patients post neoadjuvent chemoradiotherapy which has 
limited its use in clinical practise in the UK. 
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Squamous cell cancer of the upper third (cervical) oesophagus tends to be 
treated with chemoradiotherapy. If surgery is performed then the pharynx, 
larynx, thyroid and proximal oesophagus are removed along with a radical neck 
dissection. This procedure is associated with major morbidity. As survival is the 
same for this group of patients whether chemoradiotherapy or surgery is 
performed, chemoradiotherapy is preferred to avoid the morbidity of 
surgery(106).  
Chemoradiotherapy is also offered to patients with upper or middle squamous 
cell carcinoma who are not fit for surgery or have an unresectable primary 
tumour. Evidence from case series and randomised trials suggest that non 
surgical treatments are well tolerated and have equivalent outcomes to surgery 
in many patients (107-109). Chemoradiotherapy offers a 27% 5 year 
survival(110).However it is noted that the drawback to chemoradiotherapy is 
persistent or locally recurrent disease(111). There is little evidence for the use 
of chemoradiotherapy as a primary treatment for oesophageal adenocarcinoma.  
 
1.7.3 Palliative Therapy 
1.7.3.1 Endoscopic Treatment 
 
Locally advanced oesophageal cancer which is inoperable with or without distant 
metastatic disease may be treated with a combination of modalities. Patients’ 
optimal treatment should be decided by MDT agreement and patient discussion. 
Symptomatic treatment is important with dysphagia being the main symptom 
requiring palliation. Dysphagia may be treated endoscopically with self 
expanding metal stents, YAG laser and balloon dilatation.  
 
Chapter 1  37 
1.7.3.2 Chemotherapy 
 
Chemotherapy can treat the primary oesophageal cancer distant metastases. 
Chemotherapy has been shown to have both symptom improvement and survival 
benefits compared to supportive care only (112-114). However response to 
chemotherapy is short, usually a few months and patients rarely survival beyond 
twelve months(115). The usual agents are epirubicin, cisplatin and 5-FU and can 
reduce the tumour by 20 to 50%. Further trials have been ongoing to explore 
oxaliplatin and capecitabine. The REAL-2 randomised controlled phase III 
trial(116) compared ECF, ECX (epirubicin, cisplatin, capecitabine), EOF 
(epirubicin, oxaliplatin, infusional 5-FU), and EOX (epirubicin, oxaliplatin, 
capecitabine).This showed no significant difference between the 4 groups in 
terms of progression free survival and response rates. However in the secondary 
analysis the median survival in patients treated with EOX was longer compared 
to ECF (median 11.2 vs 9.9 months). Oxaliplatin treated patients had less grade 
3-4 neutropenia, alopecia and thromboembolism but greater diarrhoea and 
peripheral neuropathy. This has led to changes in palliative regimes for 
advanced oesophago-gastric cancers and has led to the REAL-3 trial (currently 
recruiting) which aims to determine if the addition of panitumumab (epidermal 
growth factor receptor antibody) to EOX improves survival. 
 
1.7.3.3 Radiotherapy 
 
Palliative external beam radiotherapy (RT) can also provide symptomatic relief 
of pain and dysphagia in up to 70%(117) patients but sustained remission and 
long term survival are rarely achieved. In a series examining the difference in 
food passage scores before and after RT alone for oesophageal cancer, dysphagia 
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was improved in 71% of patients and 54% patients were adequately palliated 
until death(117).The downside to this treatment is that the duration of benefit 
may be too short in those with a survival longer than 3-6months. In two series 
where patients were treated with RT alone, 3 and 5 year survival rates were 1 
and 2%(118;119). 
In a randomised trial of RT alone for localised oesophageal cancer (mostly 
squamous) versus chemoradiotherapy at 3 years patients having RT alone had 0% 
survival. Patients having combined therapy had a survival of 27% at 5 years 
(110;120). Other series have shown slightly better survival for RT alone for 
inoperable squamous cell carcinoma of 10-15% at 4 years (117;121).  
 
Side effects of RT include post RT stricture formation and development of a 
tracheoesophageal fistula (incidence 6%(122)).Strictures may be benign fibrotic 
strictures with an incidence of 30% which generally dilate easily with patients 
having a 12 month survival of 88%(123). Strictures may also be malignant 
secondary to recurrence with a malignant stricture rate of 28%. Patients who 
develop a malignant fistula have a 12 month survival of 19%(123). 
 
1.7.3.4 Chemoradiotherapy 
 
Many randomised trials have compared combined chemotherapy with RT with RT 
alone for locally advanced inoperable oesophageal cancers; however most are 
flawed due to suboptimal RT, or chemotherapy dose or sequential delivery 
rather than concurrent. The landmark trial demonstrating survival benefit from 
combined therapy was the RTOG 85-01 trial (110;120). Patients with loco-
regional disease (T1-3, N0, M0) were randomly assigned to chemoradiotherapy 
(5FU and cisplatin) plus RT or RT (64Gy) alone. Chemoradiotherapy was 
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associated with a better median survival (14 vs 9 months) and five year survival 
(27 vs 0%). This trial led to the adoption of chemoradiotherapy rather than RT 
alone. It was noted that no T4 patients were included so the study group 
probably contained a more favourable population and the majority (85%) of 
patients had squamous cell carcinoma. Despite this chemoradiotherapy is used 
for T4 unresectable locally advanced oesophageal SCC and AC with this trial 
providing the evidence for its use. 
 
1.7.3.5 Brachytherapy 
 
Brachytherapy involves placing radioactive material directly into or near the 
cancer allowing locally high doses of radiation with preservation of normal 
tissue. A recent clinical trial from the Netherlands(124) compared brachytherapy 
to metal stents for the palliation of dysphagia. Although the stent group had a 
more rapid relief of the dysphagia, it resulted in more complications particularly 
bleeding and brachytherapy had better long term relief of dysphagia(124). 
 
1.7.3.6 Photodynamic Therapy (PDT) 
 
PDT was first introduced as a palliative treatment for oesophageal cancer but its 
role has now been extended as a first line treatment in patients with early 
cancer of the oesophagus or high grade dysplasia (HGD) within a Barrett’s 
segment where the patient is not fit enough for standard treatments. 
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1.8 Summary 
Oesophageal cancer remains a late presenting disease in the majority of cases. 
In addition in an elderly population with other medical co-morbidities this 
frequently precludes patients from radical therapy in the form of surgery or 
chemoradiotherapy. Endoscopic therapies are less invasive, with less morbidity 
and mortality and give a chance of cure in selected cases with early disease.
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2 Photodynamic Therapy 
2.1 History 
Photodynamic therapy (PDT) has recently evolved as a treatment modality in 
several different malignant and pre-malignant conditions including oesophageal, 
skin, lung, bladder, head and neck and invasive intracranial tumours. The 
treatment principle involves the administration of a photosensitising agent which 
is then activated using an external light source in the presence of oxygen. PDT 
was first introduced as a palliative treatment for oesophageal cancer but its role 
has now been extended as a first line treatment in patients with early cancer of 
the oesophagus or high grade dysplasia (HGD) within a Barrett’s segment where 
the patient is not fit enough for standard treatments.  
 
The effect of a light activated photosensitiser causing injury to living tissue was 
first observed at the beginning of the 20th century(125). In 1904 Von Tappeiner 
and Jodlbauer(126) introduced the term Photodynamische Wirkung 
(photodynamic action or effect) to describe the destruction of living tissue 
through a chemical photosensitiser interacting with visible light. It was also 
observed that oxygen was an essential component to this. Between the early 
1900s and 1970s there were only sporadic reports of photodynamic therapy(127). 
In the 1970s Dougherty and colleagues(128) observed a similar effect when a 
transplanted mammary gland tumour was sensitised using systemic 
haematoporphyrin and activated by red light of wavelength 600-700nm 
generated by an xenon lamp. This work evolved and these authors demonstrated 
that haematoporphyrin was retained in malignant tissue which when activated 
by light produced a cytotoxic effect(129). Research has continued and clinical 
photodynamic therapy (PDT) has evolved. PDT was initially used as a treatment 
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for localised, discrete, visible cutaneous lesions(130). As technology progressed 
with the development of optical fibres and endoscopic light delivery systems, 
PDT application became possible in the respiratory and gastrointestinal tract. 
 
2.2 Oesophageal Therapy 
Photodynamic Therapy has been used in the treatment of oesophageal cancer for 
the last fifteen years as a non thermal ablative technique. It requires three main 
non-toxic components: a photosensitiser, light and oxygen. It is a two stage 
process whereby a chemical photosensitiser given systemically may selectively 
concentrate in the target tissue. It has been shown that systemically injected 
porphyrin (haematoporphyrin) when activated by red light causes complete 
eradication of transplanted experimental tumours(131). This study also 
demonstrated the preferential accumulation of the photosensitiser in malignant 
tissue. The sensitised tissue is then illuminated at a wavelength that will 
activate that particular photosensitiser. After activation the photosensitiser is 
elevated from ground state to a long lasting excited triplet state. This excited 
molecule can then react with cell membranes to form radical ions which interact 
further with oxygen to produce cytotoxic oxygenated molecules. Alternatively 
the excited molecule can transfer the energy directly to an oxygen molecule to 
generate a reactive oxygen species (ROS) which is also highly cytotoxic. Both 
these reactions occur simultaneously.  
 
The photosensitiser accumulates in the mitochondria where it is synthesized 
(127;132)  more so in tumour cells than normal tissue at a ratio of 2:1. This is 
most likely due to the tumour tissue’s high vascular permeability, lack of lymph 
drainage and greater affinity for proliferating endothelium. The photosensitiser 
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aggregates are relatively large and so prevents rapid clearance from tumour 
interstitial fluid and hence uptake in lipophylic components of the cell(133). 
Tumour destruction then occurs by direct killing by ROS and damage to tumour 
vasculature hence tumour infarction.  
 
Studies have also suggested that there is PDT mediated activation of an immune 
response against tumour cells. This may be mediated by the photosensitiser’s 
aggregates causing phagocytosis by reticuloendothelial cells(133). A study 
examined the immunogenicity of PDT-generated murine tumour cell lysates in a 
pre-clinical vaccine model compared with other modes of creating whole tumour 
cell vaccines such as UV or ionizing radiation(134). This showed PDT to be more 
effective, tumour specific and appeared to induce a cytotoxic T-cell response. 
Both the UV and PDT generated tumour cell lysates were able to induce 
phenotypic dendritic cell (DC) maturation, only the PDT generated lysates could 
activate DCs to express IL-12 which is critical to cellular immune response 
development. This shows that the direct tumour effects of PDT play an 
important role in enhancing the host anti-tumour response. A further literature 
review (135) also concluded that PDT destroys the structure of the tumour 
thereby enabling the immune cells in the tumour stroma to directly interact with 
the tumour cells resulting in a systemic anti-tumour immune response. The 
majority of studies showing that local PDT of tumours enhances systemic anti 
tumour immunity are pre-clinical. There are two clinical case reports supporting 
the in vivo evidence though not yet in oesophageal disease(136;137). Basal cell 
carcinoma (BCC) has been treated with PDT and the systemic immune response 
to its tumour antigen Hip1 has been studied(136). BCC lesions were either 
treated with PDT or surgically removed. Blood was collected from patients 
before and 7-10 days after treatment. Peripheral blood leucocytes were isolated 
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and reactivity to the Hip antigen measured. Immune recognition of the Hip1 
antigen was significantly increased in the patients treated with PDT compared to 
those having surgical removal. A further case report looked at the immune 
response against angiosarcoma following PDT(137). A patient with recurrent 
multifocal head and neck angiosarcoma was treated with a chlorine based 
photosensitiser and the lesions irradiated with 665nm light. A year later the 
lesions recurred and were re-treated at a lower fluence rate - which made 
adjacent untreated lesions spontaneously disappear. Biopsy samples underwent 
immunohistochemical analysis which suggested PDT could have activated a cell 
mediated immune response against the untreated lesions. Further clinical 
studies are required to support the ongoing pre-clinical work. 
 
2.3 Photosensitisers  
The photosensitisers which have been used in oesophageal cancer are porfimer 
sodium (Photofrin, Pinnacle Biologics, USA), a second generation synthetic 
photosensitiser meta-tetrahydroxyphenylchlorine (mTHPC) (Temoporfin, Foscan, 
Biolitec Pharma, Ireland) and 5 aminolaevulinic acid (5ALA) (Medac, Germany) in 
early oesophageal cancer(138).  
 
2.3.1 Photofrin 
This is a haematoporphyrin derivative which has been partially purified in its 
commercial preparation as porfimer sodium. It is a first generation 
photosensitiser and was first to be approved for use for PDT for oesophageal 
cancer. It is given intravenously and reaches peak concentration within 48 
hours(139;140). It is then activated using red light of wavelength 630nm at a 
light dose greater than 100J/cm. It has a deeper penetration than 5ALA giving a 
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depth of necrosis of 6-7mm(141).Patients continue to have cutaneous 
photosensitivity for up to 60 days post procedure. 
 
2.3.2 Aminolaevulinic acid (5ALA) 
This is a naturally occurring compound in the haem biosynthetic pathway and is 
produced in every nucleated cell. 5ALA has no innate photosensitising properties 
but is metabolised to the photosensitive compound protoporphyrin IX (PpIX) 
when taken orally or given topically with time to peak concentration being 6-8 
hours. This means there is a reduced duration of photosensitisation and PpIX has 
an affinity for epithelial cells and so has a more selective effect in 
gastrointestinal mucosa with less damage to underlying tissues. The depth of 
necrosis produced is 2mm(142;143) so there is less likely to be complications 
such as stricture formation and perforation. 5ALA is activated with red light at 
wavelength 635nm. 
 
2.3.3 m-Tetrahydroxyphenylchlorine (mTHPC) 
This is a second generation photosensitiser and a chlorine. As a chemical it is 
pure and stable with a strong absorption peak at 652nm of red light (this 
wavelength penetrates tissues slightly better than the 630nm used for porfimer 
sodium allowing a deeper effect of 5-10mm depth of necrosis (144;145)). This 
also means clinical effect can be achieved at lower light doses (10 to 20J/cm) 
and reduce the treatment time with a shorter duration of photosensitivity. It is 
also activated by green light at wavelength 514nm(146) which penetrates less 
than red to minimise muscle damage. Serious complications with 
aortoesophageal and tracheosophageal fistula formation have been documented 
with red light. Green light is safer but with shorter duration of effect for 
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ablation of HGD in Barretts(146). Due to these complications mTHPC is not 
currently used to treat oesophageal disease. 
The photosensitiser properties are shown in Table 1. 
 
Table 1 The properties of Photosensitisers 
 Route of 
Admin-
istration 
Dose 
(mg/Kg) 
Time to 
peak 
concent-
ration (h) 
Light 
Activation 
(nm) 
Depth of 
Necrosis 
(mm) 
Porfimer sodium 
(Photofrin, Pinnacle 
Biologics, USA) 
IV 2 48 
(139;140) 
Red 630nm 6-7(141) 
m-
Tetrahydroxyphenylch
lorine (mTHPC) 
(Foscan, Biolitec, 
Pharma, Ireland)  
IV 0.15 96 Red 652nm 
Green 
514nm(146) 
5-10 
(144;145) 
5 Aminolevulinic acid 
(5ALA) (Medac, 
Germany) 
PO(147) 60 6-8 Red 635nm 2(142;143) 
 
 
2.4 Pharmacokinetics 
The pharmacokinetics of Photofrin (haematoporphyrin derivative ) was initially 
studied in mice(148) and has shown multi-phasic plasma clearance kinetics with 
an initial rapid decline in concentration followed by a much slower  reduction 
(Figure 5)(149).  
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Figure 5 Pharmacokinetics of Photofrin (porfimer sodium) 
Serum concentration of porfimer following 2mg/Kg IV injection administered on 
two different occasions 30-45 days apart.(149) 
 
 
 
The drug is eliminated in urine and faeces, more so in the latter. This would 
explain the prolonged photosensitivity that is experienced by patients 
undergoing PDT with this study showing residual photofrin still detectable at 75 
days after initial injection. Recently the pharmacokinetics of receiving two 
intravenous injections of photofrin within 30-45 days of each other has been 
studied(149).  
 
If a tumour has been unresponsive to the first PDT treatment in terms of no 
improvement in endoscopic appearances or dysphagia for palliative patients or 
continued malignant biopsies if the treatment was given with curative intent, 
then a second PDT treatment may be carried out. In this situation the levels of 
porfimer sodium in plasma are higher after the second administration suggesting 
there is some accumulation of the drug after repeat administration(149). The 
mean elimination half life after the first administration was 410 hours increasing 
to 725 hours after the second(149). Despite this there was no significant increase 
in adverse events.  
Chapter 2  48 
 
Photofrin localises in organs rich in reticuloendothelial cells such as liver, spleen 
and kidney and is lowest in skin and muscle(148). Adrenal glands, pancreas and 
urinary bladder also all retain high levels of Photofrin. Formed blood elements 
remain free of photosensitiser but mast cells and macrophages accumulate large 
amounts and once activated by light release vasoactive inflammatory and 
immune mediators.  
 
In malignant tissue photosensitiser drug uptake is significantly greater than in 
normal tissue(140). The preferential retention of photosensistiser in tumour 
tissue has been studied and is most likely due to a combination of factors 
including in altered tumour micro-environment, increased lipoproteins receptors 
on the cell surface of tumours and uptake by tumour associated 
macrophages(128). There is evidence that there is increased uptake in the upper 
GI system, with increased concentrations of Photofrin in upper GI organ tumours 
(gastric/small bowel) compared to colon and sarcoma(140). This may reflect the 
high vascularity and low density of reticuloendothelial cells in these organs. 
 
2.5 Light Dosimetry 
2.5.1 Photofrin 
Previous studies have already investigated the light dosimetry required to 
produce adequate tumour necrosis with minimal healthy tissue damage. A 
preliminary randomised trial assessed various doses of 630nm light in 10 of 32 
patients comparing Photofrin PDT and Nd:YAG laser for palliative treatment of 
malignant oesophageal obstruction(150). This showed light dosimetry correlated 
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with depth of tumour necrosis (p<0.001) with 300J/cm being recommended as 
the optimal light dose for palliation of oesophageal carcinoma(150).  
 
Now that  porfimer sodium PDT is being used for early cancer and HGD in 
Barrett’s epithelium(70) a lesser depth of necrosis is required otherwise there is 
a high incidence of stricture formation. A non randomised dose de-escalation 
study has been carried out to find out the lowest dose effective for HGD/T1 
cancer ablation whilst reducing stricture incidence(151). This confirmed that 
post procedure stricture formation was directly related to light dose delivered 
and therefore the depth of tumour necrosis produced. At 115J/cm 15.3% of 
patients developed severe strictures (where more than 6 dilatations were 
required) and 17% of patients had residual HGD/T1 disease. At 85J/cm 5.6% 
patients had severe strictures but 31.6% of patients had residual HGD/T1 
disease. This showed that decreasing the light dose reduced the incidence of 
stricture formation but it also increased the risk of residual disease. It has also 
been shown that increased length of light exposure at lower energy is of benefit 
in rat models producing a greater degree of tumour necrosis(152). This paper 
also demonstrated that oxygen levels in the tumour tissue fell more rapidly at 
the higher rate of light delivery therefore the tumour would have become devoid 
of oxygen required for PDT activation. 
 
 Although PDT is used to treat many solid tumours using empirical treatment 
parameters it is likely that the optimal photosensitiser dose, light dose and rate 
of light delivery have yet to be achieved. The UK PDT clinical study Group 
recommend a total light dose of 200J/cm with porfimer sodium given at 
2mg/Kg(153). Our Unit’s policy for the treatment of HGD or early T1 tumours 
with Photofrin is to use a light dosimetry of 100J/cm with 300J/cm reserved for 
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the palliation of advanced oesophageal carcinoma. Clearly further studies are 
required to define the optimum laser light dosimetry for treatment of both pre-
malignant and malignant lesions.  
 
2.5.2 5ALA 
ALA PDT is usually activated using red laser light at 635nm, though can be 
activated with green laser light at 514nm.Actual light dosimetry has been 
assessed in one study by measuring the fluence rate (light delivery rate) of three 
components - the therapeutic laser light and fluorescence emission from PpIX, 
the fluorescence emission from PpIX  alone and the fluorescence from the 
oxidisation product of the photosensitiser(154). This revealed that at the onset 
of light activation a significant contribution to the 635nm signal is due to 
fluorescence from PpIX which would allow therapeutic light exposure to be 
reduced with no loss in clinical efficacy but improvement in patient tolerance of 
treatment(154).A further study has investigated the effectiveness of differing 
the light doses for the treatment of HGD in Barrett's oesophagus with ALA(155). 
Patients received 5ALA orally (60mg/Kg) and were activated by low (500J/cm), 
medium (750J/cm), high (1000J/cm) and highest (1000J/cm x2) light dose at 
635nm. Successful eradication of HGD was significantly correlated with light 
dose (p<0.01). The study recommends a minimum light dose of 1000J/cm with 
drug dose 60mg/Kg for eradication of HGD in Barrett's oesophagus(155). 
 
2.5.3 mTHPC 
Light dosimetry in mTHPC PDT has been examined in pre clinical studies only. A 
study using a sheep model investigated the effects of light doses from 10 to 
500J/cm at 514nm and 5-250J/cm at 413nm after injection of 0.15mg/Kg of 
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mTHPC(156). Follow up endoscopies revealed a tissue response at all light doses, 
though the extremely high doses induced circumferential necrosis with 
subsequent stenosis. With green light scarring was evident at light doses greater 
than 100J/cm and with blue light extensive fibrosis was noted only at 175-
250J/cm. This paper suggested blue light may be considered an alternative for 
more superficial oesophageal cancer(156). 
mTHPC currently only has a license in Europe for the palliative treatment of 
head and neck cancers. 
 
 Although photosensitisers are currently activated by lasers it may be possible to 
achieve this simply by white light illumination from the endoscope alone over a 
prolonged period of time. This would significantly increase the applicability and 
cost effectiveness of the treatment and studies are currently assessing this(157). 
 
2.6 Modes of Application of Laser Light 
Laser light is delivered through the endoscope with a cylindrical diffusing fibre 
(available in different lengths) which allows circumferential illumination of large 
areas by positioning the fibre within the lumen. A number of fibre centering 
devices such as solid Perspex dilators and balloons have been developed to 
improve light dosimetry (158-160). These help flatten oesophageal folds, reduce 
any pressure on the oesophageal wall and prevent direct contact with the laser 
fibre. Balloons are available in several lengths and the use of longer balloons has 
been shown to reduce the incidence of strictures as there is less overlapping  of 
treatment areas(161). 
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2.7 Safety 
PDT is a relatively safe procedure but does have early and late complications. 
The following side effects relate to the Photofrin which is currently the only 
licensed PDT drug in the UK. 
 
2.7.1 Early Complications 
The early complications after PDT are related to local effects of tumour necrosis 
and the effect on surrounding normal tissue. These may be divided into 
oesophageal (oesophagitis(10%)(162) and dysphagia); pulmonary 
(pneumonia(163) and pleural effusions(164)) particularly middle third tumours 
from direct pulmonary or pleural PDT activation via the laser; cardiovascular 
(atrial fibrillation and cardiac failure); cutaneous (photosensitivity reaction) and 
general (fever, leukocytosis, retrosternal chest pain). 
 
2.7.2 Late complications 
Late complications relate mainly to photocutaneous reactions, stricture 
formation and late severe complications such as fistula or perforation. The 
incidence of this is summarised in Table 2.  
Table 2 Safety profile of photosensitisers 
 
 
 Photosensitisation 
reactions  
Stricture/stenosis 
requiring 
dilatation 
Perforation Fistula 
Formation 
Porfimer 
Sodium 
6-19%(164;165) 2-
50%(70;164;166) 
1-2%(164;165) 2%(163) 
m-THPC 8-10%(147) 5-8%(146;147) 5% 10.5%(147) 
5ALA 0(147;167) 0(147;167) 0(142;147;167) 0 
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2.7.2.1 Skin Photosensitivity 
Photosensitivity reactions are relatively common with patients photosensitised 
post treatment for anything up to 3 months. Patients require protective clothing 
such as hat, gloves, and sunglasses; and require to avoid direct sunlight for at 
least 30 days post procedure, with care needed beyond this for a further two 
months. The photosensitivity is due to residual drug which will be present in all 
parts of the skin. Exposure to ambient indoor light is however beneficial as the 
remaining drug will be inactivated gradually and safely through a photo 
bleaching reaction and so patients should not stay in a darkened room. The level 
of photosensitivity will vary for different areas of the body depending on the 
extent of previous exposure to light.  
 
Dermatological complications related to PDT have been studied over several 
years (168). This group noted cutaneous complications including phototoxicity 
requiring steroids (31%) (erythema, blistering, swelling and pain on sun exposed 
areas), herpes zoster (1%) and erythema multiforme drug reaction related to the 
porfimer sodium (1%). All patients responded to medical treatment with oral 
steroids and more vigilant skin protection. 
 
2.7.2.2 Strictures 
Stricture formation post treatment is the most common clinically significant 
complication requiring further therapy such as oesophageal balloon dilatation. 
Some series suggest the incidence of this may be up to 30% (158;169). As 
discussed stricture formation after PDT relates to a chronic inflammatory type 
reaction second to tumour necrosis. The ensuing healing process induces fibrosis 
within the muscularis propria layer leading to a stricture. Steroids post 
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procedure do not influence stricture formation(170). Pre-treatment variables 
associated with an increased likelihood of stricture formation have been studied 
in patients treated with porfimer sodium(171). The results as expected showed 
that Barrett’s oesophagus length and PDT treatment time were predictors of 
increased stricture rate. The number of light exposures, light dose or diffusing 
fibre rather than a balloon had no effect. There was a higher stricture rate in 
those patients with a pre-treatment stricture than those without (22% vs 7% 
p=0.03) and a higher rate in patients with intramucosal carcinoma or cancer 
compared to HGD in Barrett's oesophagus (31% vs 16% p=0.03).Previous EMR did 
not predict stricture rate. 
 
2.7.2.3 Motility 
Dysphagia post PDT is not always secondary to stricture formation and may be 
due to oesophageal dysmotility. Patients with oesophageal cancer often have a 
degree of dysmotility from their invasive disease. Oesophageal motility has been 
assessed in patients pre and post-treatment with PDT(172). Using a standard 
water based perfusion system, oesophageal motility was measured two days 
before PDT and over three weeks post-PDT. Results were classified into normal, 
ineffective motility or aperistalsis. Twenty three patients were studied, 13 with 
carcinoma, 10 with Barrett’s oesophagus. Pre-treatment results showed that 48% 
of patients had normal motility, 26% ineffective motility and 26% aperistalsis. 
Post-treatment results revealed normal motility in 26%, 30% ineffective motility 
and 43% aperistalsis (not statistically significant). These results conclude that 
whilst pre-treatment dysmotility exists motility may be compromised by PDT and 
be an alternative cause of dysphagia.  
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2.8 Buried Glands 
After PDT neo-squamous epithelium is often formed. This can lead to an added 
complication of Barrett’s oesophagus or even a buried neoplasm developing 
beneath the restored squamous epithelium. The incidence of buried Barrett’s 
oesophagus is reported to be anything between 0 and 40% (158;159;166;167;173-
176) with buried neoplasms having an incidence between 0 and 3.7% 
(158;167;174;176). Buried Barrett's oesophagus is more common after 5-
aminolevulinic acid based PDT than porfimer sodium (0% - 7.4%) 
(158;166;174;176;177).This means thorough endoscopic surveillance is required 
post- PDT treatment with careful biopsy of the neo-squamous epithelium in the 
early cases. 
 
2.9 Cost-effectiveness of PDT 
2.9.1 Barrett's HGD 
The cost effectiveness for PDT in the treatment of HGD in Barrett's 
oesophagus(178) has been studied in the USA. This study compared PDT, 
oesophagectomy and continued endoscopic surveillance of HGD in Barrett’s 
oesophagus. PDT was shown to be both efficacious in the treatment of HGD and 
cost effective. In older patients (>65yrs) PDT was more effective and less costly 
when compared to oesophagectomy. 
PDT’s advantage over surveillance is that in many it will prevent progression to 
cancer and hence cancer related deaths.  This study has shown that PDT is more 
effective than either surveillance or oesophagectomy. PDT also resulted in 
longer unadjusted life expectancy compared to surveillance or oesophagectomy. 
PDT did cost more but was $12400/QALY (quality adjusted life year) compared 
to oesophagectomy of $3300/QALY(178). The paper interestingly noted that 
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colon cancer screening with colonoscopy is $11000/QALY and annual 
mammography is $22000/QALY. All of these figures show that PDT as an initial 
treatment of Barrett’s oesophagus is reasonably cost effective.PDT has also been 
shown to be more cost effective than APC(82). 
 
2.9.2 Oesophageal Cancer 
As with any new development or treatment in medicine the question of cost 
effectiveness compared to current standard treatment has to be investigated. 
Initially PDT was used to palliate patients with oesophageal cancer who had no 
other therapy available to them. Conventional modalities for the palliation of 
oesophageal cancer are self expanding metal stents (SEMS), YAG thermal laser, 
Argon Plasma Coagulation (APC) and sometimes palliative radiotherapy. There 
are no randomised trials comparing all of the above palliative therapies in terms 
of efficacy or cost effectiveness. A  randomised controlled trial of the cost 
effectiveness of non- PDT palliative therapies for patients with inoperable 
oesophageal cancers has been performed (179). The cost effectiveness of SEMS 
compared with plastic stents or non stenting palliative therapies (laser, APC, 
bipolar coagulation and ethanol induced tumour necrosis) was evaluated in 
patients with inoperable oesophageal cancer. Unfortunately PDT was not 
assessed in this set of patients. However the results showed similar costing of 
SEMS and non-SEMS therapies. Although a survival benefit in non-SEMS treated 
patients was noted there was a significant delay to their treatment and length of 
stay accounted for most of the cost entailed in the NHS.  
 
This group(180) has published a cost comparison of photodynamic therapy and 
metallic stents in the palliation of oesophageal cancer. This study involved a 
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combination of prospective and retrospective data from patients having the 
above two therapies with costs estimated using routine costs for the year 2001-
2003. Patients were age and sex matched with similar tumour presentation. 
Overall PDT patients had shorter duration of symptoms and less metastatic 
spread but similar dysphagia scores than those patients with a stent. Although 
the cost of initial PDT treatment was higher and there was a higher cost related 
to re-intervention, patients receiving PDT survived longer. When evaluated 
overall the mean cost per day’s survival was equivalent between the two groups. 
There have been no other cost effectiveness analyses in the UK to date. 
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2.10 Aim 
This unit has used Photodynamic therapy to treat HGD in Barrett’s oesophagus, a 
pre malignant disease; early oesophageal cancer in patients unfit due to medical 
co-morbidity for surgical resection and to palliate advanced oesophageal cancer. 
This thesis explores the role of PDT in the treatment of neoplastic disease of the 
oesophagus.
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3 Photodynamic Therapy Successfully Ablates 
High Grade Dysplasia in Barrett's Oesophagus 
3.1 Introduction 
 Barrett’s oesophagus (specialised intestinal metaplasia) is a pre-malignant 
condition which may progress through low grade dysplasia (LGD), high grade 
dysplasia (HGD) to invasive adenocarcinoma although the transformation rate 
may vary worldwide from 0.2% to 2%(181-183).There is an increased incidence of 
Barrett’s oesophagus(184) which parallels that of oesophageal 
adenocarcinoma(6).  
 
Overall the annual incidence of development of adenocarcinoma in Barrett’s 
oesophagus is approximately 0.5% per year, representing at least a 30 to 40 fold 
increase in risk from the general population (185). This risk has been shown to 
be increased in longer lengths of Barrett's oesophagus (186;187) with a threshold 
analysis suggesting 6cm as a cut-off length at which the risk of progression to 
dysplasia or adenocarcinoma is increased (188). The highest risk for the 
development of oesophageal adenocarcinoma is HGD with 30–59% of HGD 
patients progressing to oesophageal adenocarcinoma within 5 years (189;190). In 
addition to the high rate of oesophageal adenocarcinoma development in 
patients with HGD, unexpected cancer has been found in up to 50% of 
oesophageal resections for HGD (191;192).Controversy exists as to whether this 
high number of occult malignancies in oesophagectomy specimens results from 
progression of HGD to adenocarcinoma or from a missed cancer and sampling 
error during surveillance. Sampling error is more likely as most recent evidence 
suggests that with the development of enhanced imaging endoscopy (NBI, AF) far 
more cancers are detected early. 
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 The natural history of Barrett’s oesophagus has been studied(193).Not all 
patients with HGD will progress to adenocarcinoma and in fact some may 
regress. A retrospective case note review of all patients with HGD in Barrett’s 
oesophagus(193) has demonstrated regression in 13% (4/29) of patients who were 
managed by endoscopic surveillance alone. A further retrospective study has 
also shown 31% of their patients with HGD under endoscopic surveillance regress 
over 3 years(194).However, the general consensus is that HGD  confirmed on at 
least two occasions by expert pathologists should be regarded as a pre-malignant 
condition which requires active treatment (195). 
 
The previous gold standard treatment for HGD in Barrett’s oesophagus was 
oesophagectomy; however this is not suitable for all patients as many are elderly 
with multiple medical co-morbidities with significant  associated morbidity and 
mortality related to surgical resection (2-3%)(196). Recently newer organ 
preserving techniques have been developed to treat HGD including endoscopic 
mucosal resection (EMR)(197) and mucosal ablative techniques like 
photodynamic therapy and radiofrequency ablation(92;198).  
 
PDT has several advantages over surgery in that it is comparatively simple, non 
invasive, can be targeted accurately and can be used repeatedly without dose 
limitations. PDT is also safe for use after other therapies such as EMR and laser. 
In a randomised control trial of PDT and acid suppression (with use of proton 
pump inhibitor (PPI)) versus PPI alone, the 5 year follow up showed ablation of 
HGD in 77% of patients receiving porfimer sodium PDT compared with 30% 
treated with acid suppression therapy alone (p<0.001)(199). Progression of 
cancer occurred in 15% of patients in the PDT group compared to 29% of patients 
receiving acid suppression alone(199). This represented a 50% decrease in 
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oesophageal cancer development and was the first randomised trial of 
endoscopic therapy to show such a benefit. The Mayo clinic  have also 
retrospectively shown comparable 5 year survival rates among HGD patients 
undergoing oesophagectomy and those HGD patients having PDT(200). 
 
Patients appear to have a high level of satisfaction when treated with PDT for 
HGD despite reporting post treatment problems with odynophagia or 
dysphagia(201). There is as yet no prospective randomised study comparing 
oesophagectomy and PDT and so the optimal treatment remains unknown.   
 
This group has extensive experience with PDT, initially in the palliative care 
setting and then latterly for early oesophageal cancer and for HGD in Barrett’s 
oesophagus. The most recent guidelines from the National Institute for Health 
and Clinical Excellence (NICE) 2010 states that PDT for HGD in Barrett’s 
oesophagus is effective with no major safety concerns and may be used by 
endoscopists with specific training in this area after patient selection has been 
discussed by a multidisciplinary team(202).Although PDT has largely been 
superseded by RFA in many specialist centres, the long term benefit of RFA in 
Barrett’s HGD remains unknown. 
 
3.2 Aim 
This study aimed to assess the long term efficacy of PDT in patients with 
Barrett’s HGD. 
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3.3 Patients and Methods 
Between June 2002 and 2007, 21 patients, 16male of median age 70 (range 53-
84) in our unit who were unfit for oesophagectomy secondary to medical co-
morbidity or poor performance status, were treated with PDT for HGD in 
Barrett’s oesophagus. High grade dysplasia was diagnosed on two separate 
occasions using the Seattle Protocol(43) by a dedicated specialist Barrett’s 
pathologist. All patients were discussed at the regional MDT meeting and were 
given both written and visual information regarding this treatment.  
 
All patients were treated as inpatients as the unit is a tertiary referral centre 
covering a wide geographical area. Each patient received the photosensitiser 
Photofrin (Porfimer sodium) intravenously at 2mg/kg body weight over 3 to 5 
minutes. Forty eight hours later the photosensitiser was activated by laser light 
at 630nm via a 2.5 – 5.0cm endoscopic fibre with a light dose of 100 to 200J/cm. 
The light dose delivered was reduced during the time period as further evidence 
indicated a lower optimal light dose for mucosal disease. Patients received high 
flow oxygen 2 hours pre and post procedure. After the procedure patients 
remained on long term high dose proton pump inhibitor. Patients returned at 6 
to 12 weekly intervals for repeat endoscopy and biopsy. The end point of data 
collection for the purpose of this thesis was HGD recurrence, progression to 
cancer or death. Data collection was completed in January 2012 
 
3.4 Results 
All patients had HGD in Barrett’s oesophagus on their initial biopsies. Four had 
had previous EMR for nodular Barrett’s containing intramucosal adenocarcinoma 
(one) or T1 adenocarcinoma (three). Median follow up is 62 months (range 2 to 
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114 months). Five have now died from non treatment or non oesophageal cancer 
related causes: pulmonary embolus, incarcerated inguinal hernia, pneumonia 
and myocardial infarction. One patient has been discharged to further follow up 
at 5 years. Twenty patients of the 21 treated were followed up with one patient 
dying of a non procedure related cause (pulmonary embolus and renal failure) 3 
weeks post PDT but before she had a follow up endoscopy. As there was no 
endoscopic or histopathological evidence of the response to PDT twenty patients 
only have been evaluated. 
 
Overall 16 of 20 patients remained free of HGD at median 62 months. The 
overall mean number of PDT sessions per case was 1.5 (range 1-2). 
Three patients developed adenocarcinoma at 47, 48 and 54 months (15%). Of 
these one had intramucosal carcinoma only, successfully treated with EMR and 
RFA with squamous cell epithelium only at most recent biopsy. One patient had 
neoadjuvant chemotherapy and surgical resection with final pathology of ypT2 
ypN0 and the third patient had YAG laser. Of the other patients, 2 had Low 
Grade Dysplasia (LGD) and 14 had intestinal metaplasia on their final follow up 
biopsies. This represents successful ablation of HGD in Barrett’s oesophagus in 
80% of patients.  
 
Four of 20 patients had HGD persisting on their first biopsy 6 weeks post PDT so 
were initial non responders. Of these, three received further PDT sessions of 
which one died before further repeat biopsies were taken (died of complications 
secondary to surgery for an incarcerated hernia). The other 2 with further PDT 
sessions responded and remained free of any dysplasia. The 4th non responder 
had no further treatment but on further multiple biopsies had only LGD present. 
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During the treatment period 4/20 developed recurrence of the HGD (at 4, 9, 16, 
19 months respectively). Three patients had repeat PDT and one patient had 
radiofrequency ablation. All four patients remained free of dysplasia. There was 
no pattern to the recurrence of HGD or development of adenocarcinoma. Only 
one recurrence occurred in an initial non responder. The site of recurrence or 
adenocarcinoma was the original site treated.  
 
All patients had a median of 5cm Barrett’s segment (range 1-12cm) pre PDT. 
There was a significant reduction in the length of Barrett’s segment post PDT 
median 3cm (range 0-10cm) p=0.035 Wilcoxon Signed Rank test (Graph 2). 
Graph 2 Reduction in length of Barrett's oesophagus post PDT for HGD 
 
3.5 Complications 
Seven of twenty patients required endoscopic dilatation a median of 4 times 
(range 1 to 6) (35%). There were 2 patients (10%) who developed photosensitivity 
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reactions which did not require any treatment. There were no procedure related 
deaths. 
 
3.6 Discussion 
PDT is an effective treatment for HGD in Barrett’s oesophagus with 80% of 
patients having eradication of HGD at a median of 5 years. Our results are 
slightly better than the previously reported randomised control trial of PDT and 
acid suppression (with use of PPI) versus PPI alone(199) although with smaller 
numbers. Their 5 year follow up showed ablation of HGD in 77% of patients 
receiving porfimer sodium PDT with acid suppression therapy. The Mayo clinic 
have also retrospectively shown comparable 5 year survival rates among HGD 
patients undergoing oesophagectomy and those patients having PDT(200). 
Patients appear to have a high level of satisfaction when treated with PDT for 
HGD despite post-treatment problems such as odynophagia and dysphagia(201). 
There is no randomised study comparing oesophagectomy and PDT so the 
optimal treatment for HGD in Barrett's oesophagus remains unknown.  
 
The cancer progression rate in this series was 15% which is similar to other 
groups(199) using PDT to treat HGD (15%). It is however greater than groups of 
patients with HGD treated with radiofrequency ablation (RFA)with current 
studies revealing a cancer progression rate of 2.4% (203).These figures do, 
however, relate to specialist units with a lack of long term efficacy data. A 
further point to consider is the Barrett's cancer conversion rate. Our West of 
Scotland group has shown a cancer conversion rate of 0.5% per annum which is 
much higher than areas such as Denmark with a cancer conversion rate of 
0.2%(204). This suggests our population has more aggressive Barrett's epithelium 
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and hence our high cancer progression rate of 15% should be interpreted in this 
light. 
 
 The cancer progression rate in this study does need to be kept in perspective in 
considering the group of patients this treatment was aimed at who had a high 
mortality rate from non cancer causes  with  6 out of 21 patients dying from non 
cancer related causes giving a 30% mortality over 5 years. 
 
Although all patients had residual Barrett’s following PDT there was a significant 
decrease in the Barrett’s segment length. Residual Barrett’s does appear to have 
a malignant disposition with development of metachronous lesions in up to 11-
30% of cases (205;206) and therefore complete eradication of Barrett’s remains 
the optimal goal. It is interesting, however that despite the recent concern 
about residual Barrett's after endoscopic therapy this study did not demonstrate 
such a high cancer conversion rate. Patients who developed adenocarcinoma and 
recurrence of the HGD in Barrett’s did so at the same site as the initial 
dysplastic biopsies.  
 
Although mucosal ablation of Barrett’s HGD with RFA appears more effective 
with fewer complications PDT may remain an option for RFA failures where co-
morbidity may preclude surgical resection as a salvage treatment or in situations 
where RFA would not be appropriate such as residual or recurrent HGD post 
radical chemoradiotherapy. Long term follow up of patients treated with RFA for 
their Barrett’s HGD is also awaited. 
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3.7 Conclusion 
Photodynamic Therapy successfully abates High Grade Dysplasia in Barrett’s 
oesophagus and is an effective treatment for those who are elderly or with 
multiple medical co-morbidities unable to undergo oesophagectomy. 
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4 The Treatment of Early Cancer with 
Photodynamic Therapy 
4.1 Introduction 
As previously stated, prior to the advancement of endoscopic therapies 
oesophagectomy was the standard treatment for oesophageal cancer. However 
oesophagectomy is associated with both a high morbidity and mortality and also 
has been shown to have a significant negative impact on quality of life(207). 
With an ageing population many patients are either unfit for this treatment or 
refuse such aggressive treatment. This has led to the development of alternative 
endoscopic therapies such as PDT, neodymium- doped-yttrium-aluminium-garnet 
(Nd:YAG) laser thermal photo-ablation, argon plasma coagulation (APC), 
endoscopic mucosal resection (EMR) or a combination of the above.  
 
PDT involves pre-treatment with a photosensitiser and then activation with red 
laser light to produce focal tissue destruction. Photofrin (porfimer sodium) 
penetrates to a depth of 6-7 mm through mucosa, sub mucosa and muscularis 
propria (Figure 6) making it an attractive treatment for early invasive lesions 
and a real alternative for patients unable to have oesophagectomy.  
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Figure 6 Depth of necrosis of PDT 
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4.1.1 Evidence 
The feasibility of PDT as a curative treatment for early oesophageal cancer has 
previously been assessed in 123 patients( 104 squamous cell cancers)(208).Eighty 
out of 88 patients were staged as T1 or T2. PDT was part of a multimodal 
therapeutic approach in 67 of the patients with radiotherapy applied in 58 cases 
2 months after PDT and combined chemotherapy and radiotherapy in 18 of the 
patients. Nine patients had chemotherapy alone with PDT. Complete response 
was shown in 91% in the T1 group and 78% in the T2 group, this was not 
statistically significant. Overall recurrence rate was 36% at 12-18 months with a 
higher preponderance of adenocarcinoma: squamous carcinoma at 5:1.Patients 
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who recurred did respond to repeat PDT sessions. Recurrence rates were 75% for 
adenocarcinoma and 28.5% for squamous carcinoma, however subgroups such as 
T1/T2/PDT alone or combination was not analysed. Five year survival was 33% in 
T1 and 36% in T2 groups. This relatively low survival rate does reflect the clinical 
co-morbidity of the patients studied with 62% of patients who died during follow 
up dying of non cancer causes.  
 
Other groups have demonstrated similar results. A further cohort of 31 patients 
were treated with PDT; 15 with HGD in Barrett’s, 10 with intramucosal 
adenocarcinoma (IMC) and 6 with T1b or limited T2 oesophageal 
adenocarcinoma(209).In patients with HGD or IMC 80% had an initial complete 
response with 9% having a partial response. Seventeen percent developed 
recurrent HGD but 71% had a permanent complete response. 
 Adenocarcinoma developed in 19% (4/21.) Of the T1b or limited T2 
adenocarcinoma (6 patients) with mean follow up of 22 months one remained 
disease free, 2 died at 24 and 46 months (1 cancer related and 1 from unrelated 
causes). One patient had tumour recurrence at 17 months and had further PDT 
treatment, whilst the other two had recurrent adenocarcinoma but remained 
alive at 15 and 19 months after the initial treatment. 
 
There are further case series with 24 patients with early carcinoma of the 
oesophagus (21% adenocarcinoma) treated with porfimer sodium PDT with a 
complete response rate in 75% patients, recurrence rate of 17% with overall 
survival at end of follow up of 75%(210).Another study with 42 patients  with 
early oesophageal cancer treated with sodium porfimer PDT had a 3 and 5 year 
absolute survival of 72.5% and 53.8% (211). 
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Overall current evidence suggests that PDT with sodium porfimer can be a 
curative option in patients with early oesophageal cancer being particularly 
useful in patients with significant co-morbidities or poor performance status 
precluding curative surgery or chemoradiotherapy. 
  
4.2 Aim 
The aim of this study was to examine the efficacy of PDT in the treatment of 
early oesophageal cancer. 
 
4.3 Patients and Methods 
Between 2002 and 2011 38 patients, 21male, median age 72y (52-90y) were 
treated with PDT with curative intent for early oesophageal carcinoma in our 
surgical unit. These patients were staged and deemed to have early disease 
using endoscopy and CT, and then later 23/38 patients were staged with 
EUS/CT. These patients were deemed unsuitable for major surgery on the basis 
of their co-morbidity, hence PDT was offered as their definitive treatment. 
Patients were prospectively audited and followed up collecting data from 
endoscopy records, pathology, radiology reports and case notes. 
 
All patients had a least two sets of endoscopic biopsies confirming the presence 
of carcinoma of which 73% were adenocarcinoma and 27% squamous cell 
carcinoma. Table 4 summarises patient’s demographics, histology and EUS 
findings. One patient had extensive lymphadenopathy in keeping with their 
known chronic lymphatic leukaemia (CLL) so no biopsy at EUS was attempted 
although the staging was T1N1.Five patients had EMR prior to PDT treatment. 
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Table 4 Early cancer patients Demographics 
 
 
4.3.1 PDT 
Informed consent was given by the patients after they had been counselled both 
verbally and with written and visual information. The major adverse events 
particularly the photosensitisation was explained. Protective clothing in terms of 
hat, sunglasses and gloves were provided for the patients and advice given to 
stay out of direct sunlight for the ninety days post procedure. 
Each patient had their treatment as an inpatient. They received intravenous 
Photofrin (porfimer sodium) at 2mg/kg and then had an endoscopy 48 hours later 
under intravenous sedation using midazolam. A laser light 630nm via a 2.5 – 
5.0cm fibre was passed endoscopically to the level of the tumour and a light 
dose of 300J/cm applied. Patients received high flow oxygen for at least two 
hours pre and post-procedure.  
All patients n=44   
Age Median 72y  Range (52-90y) 
Sex Male 21 (55%) Female17 (45%) 
   
Histology Adenocarcinoma 20/38 (53%) 
 Intramucosal 
Adenocarcinoma 
 
 7/38 (18%) 
 Squamous cell carcinoma  8/38 (21%) 
 Intramucosal Squamous 
cell carcinoma 
 3/38 (8%) 
   
EUS staging n=23 T0N0   n=1 
 T1N0   n=21 
 T1N1   n=1 (CLL) 
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4.4 Follow Up 
 Patients were followed up at 6 weekly intervals with endoscopy and biopsy. 
Thereafter they had a repeat endoscopy every 6 weeks to 3 months dependent 
on their pathology. Four quadrant 2 cm biopsies were taken from the Barrett’s 
segment and the previous tumour site specifically biopsied as were any further 
nodular areas.  
4.5 Survival 
Overall survival post treatment was calculated from the date of the 1st PDT 
episode to time of death or completion of the audit period (01/12/11). Disease 
free survival was calculated from the date of the 1st PDT episode to date of 
death or recurrence. 
4.6 Results 
Patients follow up was a median of 40 months (range 1 to 123 months). 
Average hospital stay was 5 days. 
 
4.6.1 Response to Treatment 
A complete response was considered if the first set of biopsies post PDT were 
negative for cancer. In this cohort of patients 26/38 (68%) had a complete 
endoscopic and histological response between 6 and 8 weeks post PDT (Figure 7). 
There were 11/38 (30%) non-responders with endoscopic or histological evidence 
of ongoing presence of tumour 6-8 weeks post treatment. One patient died 
before their first post procedure endoscopy due to a non tumour related cause. 
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Figure 7 Response to PDT in early cancer 
 
 
4.6.1.1 Complete response 
Out of the 26 patients with an initial complete response, 9 remained disease 
free, 13 developed recurrent carcinoma and 4 developed high grade dysplasia. 
Time to recurrence was a median of 8 months (3-40months). 
All patients had further treatment summarised in figure 8. The four patients 
with HGD had the following further treatment: 
 One had further PDT with complete response. 
 Two had EMR of nodular lesions followed by laser (one) and RFA (one) for 
residual disease. Both are currently disease free and alive 
 The fourth patient is undergoing YAG laser. 
Of the thirteen patients who developed recurrent carcinoma: 
 Nine patients had further courses of PDT. Five had complete response to 
PDT after the second treatment. Of these three had further recurrence 
treated with PDT. One is alive and well, one died and one has been lost to 
follow up. The other two patients developed no further recurrence, one is 
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alive and one is dead. Four of the nine patients had no further response to 
PDT. One had RFA and is disease free and alive and three had palliation 
with laser or a stent (1 alive, 2 dead). 
 One patient had chemoradiotherapy and is disease free and alive 
 One patient had palliative radiotherapy and has since died. 
 Two patients had an oesophagectomy. One patient died post op with 
respiratory complications and the second patient developed liver 
metastases within six months of his surgery, requiring palliative 
chemotherapy and has since died. 
Overall 13/26 (50%) patients with initial complete response remained disease 
free or were disease free until time of death with one or more PDT 
treatments only. A further 5 remained disease free or were disease free until 
the time of death after PDT and alternative treatments for recurrence. 
 
4.6.1.2 Initial Non- Responders 
There were 11 initial non-responders. Their treatment is summarised in Figure 8. 
 Two had further PDT alone and continued to have no response. 
 Two had PDT followed by palliative laser due to continued no response.  
 Two had repeat staging investigations and surgery. One had surgery 
performed at another centre and has been lost to follow up. One patient 
did well and remains alive and disease free today. 
 One patient received radical radiotherapy and is alive and disease free 
today. 
 One patient had chemoradiotherapy and has since died. 
 Three patients received palliation of their dysphagia with laser alone
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4.6.2 Prediction of Outcome after PDT 
There were no obvious differences in the demographics of patients who had a 
complete response and those who had no response. EUS became a standard 
adjunct for staging of oesophageal cancer in the last five years in addition to CT. 
It is more useful in early stage disease where CT often under stages. Two thirds 
of our patients (23/38) had pre-treatment EUS staging. One patient had 
extensive sub diaphragmatic lymph nodes at EUS but had a history of CLL so the 
lymph node significance was questionable. He had a complete response to PDT 
developing recurrence at about 4 years. The other 22 patients were all node 
negative. 16/23 patients with Tis/T1 disease had a complete response to PDT 
with 12 recurrences. 6/23 patients with T1 disease did not respond to PDT. 
Table 5 summarises EUS findings in the 23 patients. 
 
Table 5 Response to PDT in relation to EUS T stage. 
EUS Staging Complete response to 
PDT (no. of patients) 
No response to PDT (no. 
of patients) 
T0NO 1 0 
T1N0 15 6 
T1N1 (CLL) 1 0 
   
Total 17 6 
 
4.6.3 Survival 
All patients treated with PDT had a median survival of 47.5 months (range 2-145 
m). Patients with a complete response had a median survival of 50.5 months 
(range 2-145m) (Table 6) and patients with no response had median survival of 
32 months (range 6-95m). This is demonstrated in survival Graph 3 and was 
statistically significant p=0.008 (log rank -mantel cox). 
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Table 6 Patient survival in response to PDT 
Response to PDT Median survival (range) 
months 
Disease Free Survival 
(range) months 
All patients n=38 
 
47.5 (2-145) 8 (0-133) 
Complete response n=26 50.5 (2-145) 40 (2-133) 
   
No response n=11 32 (6-95) 0 (0-7) 
 
 
Graph 3 Total survival (months) of early oesophageal cancer patients treated 
with PDT in relation to response to treatment. 
 
 
Cancer free survival in all patients was a median of 8 months. For patients with 
a complete response median disease free survival was 40 months. This is 
demonstrated in Graph 4. 
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Graph 4 Disease free survival of early oesophageal cancer patients treated with 
PDT in response to treatment. 
 
 
Thirty three percent of patients died of other causes such as pancreatic cancer, 
bronchial cancer, colorectal cancer, myocardial infarction, cerebrovascular 
accident and septicaemia secondary to urinary tract infection. 
 
4.6.4 Complications of Treatment 
The major complication due to PDT in this cohort of patients was stricture 
formation requiring intervention in the form of balloon oesophageal dilatation. 
Twelve patients developed a stricture during their treatment needing a median 
of 1 dilatation (range 1 to 31). This gave a stricture rate of 27%. Otherwise PDT 
was fairly well tolerated except for some minor chest discomfort. This delayed 
Chapter 4  80 
only one patient’s discharge as he had developed a reactive pleural effusion 
which did not require drainage. 
 
4.7 Discussion 
PDT has been shown to have an established role in the palliation of oesophageal 
cancer(212) and has recently been shown to be effective in the treatment of 
pre-malignant disease in terms of HGD in Barrett’s oesophagus(169). Its role in 
early oesophageal cancer remains unclear. There have been a few studies 
assessing the role of PDT for true early oesophageal cancers and have shown PDT 
to be beneficial (166;206;211;213) in patients not fit for surgery due to poor 
performance status or medical co-morbidities or those unwilling to have surgery 
as their definitive treatment. 
Porfimer sodium PDT achieved a complete endoscopic and histological response 
in 68% of patients six to eight week post treatment. Other groups report very 
variable rates in the literature from 37%-87%(166;206;209;213;214).These rates 
are variable as patients with HGD are included along with T1/T2 patients, some 
groups use different photosensitisers(206;214) and others use different light 
dosimetry making comparison between groups difficult. 
 
PDT using porfimer sodium penetrates to a depth of 6-7mm thereby enabling it 
suitable for use for disease limited to mucosa or submucosa. This unit has 
previously reported that EUS predicts response to PDT by accurate T staging(70). 
It was noted at the time that the numbers were small (15 patients) but all Tis 
/T1 N0 patients had complete response with no T2/T3 patients responding to 
PDT. EUS remains an important staging tool in this subset of patients, accurately 
predicting non responders who perhaps should be considered for other 
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appropriate treatment and clearly defines early Tis or T1 cancers likely to 
respond to PDT. 
 
Endoscopic surveillance post PDT continues to be important as 65% of patients 
with initial complete response developed disease recurrence. These findings are 
similar for other series(208).In this patient cohort, 6/17 were successfully 
treated with further episodes of PDT, although further recurrence occurred in 
2/6 patients. This is an advantage of PDT in that there is no dose limitation and 
so patients who have previously responded can have repeated treatments for 
recurrent disease unlike chemotherapy or radiotherapy. 
 
In this series of patients PDT was well tolerated. Patients occasionally 
complained of chest discomfort post procedure but the main complication was 
stricture formation in 27% cases. Previous studies have shown variable rates of 
stricture formation from 6.45%(209) to 42%(215).Most strictures dilate easily 
with a balloon dilator. There was no significant correlation between number of 
PDT treatments and number of strictures requiring dilatation although this has 
been previously reported. Oesophageal stricturing occurs because of the depth 
of necrosis of 6-7mm thereby affecting the muscle layer. The depth of 
penetration does depend on light dosimetry. Certainly stricture formation has 
been lower in series treating mainly HGD where lower light doses are used(209). 
However lower light doses have been shown to reduce efficacy of PDT in the 
treatment of early cancers(151). It is hoped with better understanding of light 
dosimetry that a finer balance can be achieved between efficacy and stricture 
formation. Interestingly the stricture rate in our HGD cohort is higher than that 
in the early cancer cohort (35% vs 27%) despite a higher light dosimetry in the 
early cancers. This is more likely secondary to the small numbers in each cohort. 
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Two patients who had recurrence of cancer elected to have surgery. One patient 
died of post operative respiratory complications with pneumonia at 40 days and 
the second patient developed liver metastases 6 months postoperatively. Prior 
treatment with porfimer PDT did not make surgery technically more difficult.  
 
Oesophagectomy is still the gold standard for early oesophageal cancer but as 
previously stated it is associated with high mortality and morbidity with poor 
survival rates. Five year survival post oesophagectomy with neoadjuvant 
chemotherapy is still only 23%.As the incidence of oesophageal cancer increases 
and the general population ages, there will be more patients who are neither 
medically fit or have a suitable performance status to allow them to have 
surgical resection. With the Barrett’s surveillance programs many of these 
patients may have early stage disease which is amenable to treatment with PDT. 
 
Chemoradiotherapy is used for the curative treatment of oesophageal cancer, 
(mainly mid and upper third squamous cell carcinoma) with trials demonstrating 
results approaching those of surgery(216;217). Adenocarcinoma has also been 
successfully treated(218).Radical chemoradiotherapy requires appropriate 
patient fitness however and co-morbidity such as cardiac, respiratory or renal 
problems often precludes this treatment. Previous treatment with PDT did not 
affect outcome or the ability to have chemoradiotherapy for PDT failures, 
though most are likely to be fit for palliative treatment only. 
 
Radiofrequency ablation (RFA) of the oesophagus is a newer technique used with 
success for HGD in Barrett’s oesophagus either as a monotherapy or post EMR of 
early cancers with subsequent RFA of residual Barrett's (92). There are very few 
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papers investigating the use of RFA on early oesophageal cancer. Results of RFA 
for early squamous cell carcinoma of the oesophagus have recently been 
published(219). There were 29 patients with moderate grade squamous 
intraepithelial neoplasia, high grade squamous intraepithelial neoplasia and 
early flat type oesophageal squamous cell carcinoma with a complete response 
rate of 86% at 3 months and 97% at 12 months. The depth of tissues penetration 
with RFA is between 2-3mm which means it is suitable either for flat 
intramucosal carcinoma or in combination with EMR for a mucosal (M1-3) or 
superficial submucosal (SM1) lesions. 
 
Survival overall in patients who responded to PDT was good with a median of 
47.5 months survival. Even those patients who did not initially respond and 
required further palliative procedures or repeat PDT sessions, had median 
overall survival of 32 months. This would suggest that PDT improves survival 
even in those patients who are not disease free post procedure. 
Ten of the twenty four patients who died during this follow up died of non 
oesophageal cancer related causes (42%) reflecting the other co-morbidities 
associated with this patient population. 
 
4.8 Conclusion  
Porfimer sodium PDT is a potentially alternative curative treatment for early 
oesophageal cancer in patients with medical co-morbidities or poor performance 
status which precludes them from radical surgery or oncological therapies. 
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5 The Palliation of Oesophageal Cancer with 
Photodynamic Therapy 
5.1 Introduction 
Oesophageal cancer still presents in the majority of patients at an advanced 
stage. Endoscopic techniques have been developed to palliate oesophageal 
cancer including thermal laser, argon plasma coagulation (APC) alcohol injection 
and most recently PDT. With two thirds of patients being suitable for palliative 
therapy only PDT has been increasingly recognised as an acceptable method of 
palliation of advanced inoperable oesophageal cancer (212;220;221).  
 
 The predominant symptom requiring palliation is dysphagia in more than 70% 
patients (222).The optimal palliative method would involve decreased 
dysphagia, low complication rates, improved quality of life,  minimal re-
intervention and improved survival. Unfortunately to date no one technique has 
achieved all these goals.  
 
 Apart from the above endoscopic methods other palliative options are self 
expanding metal stents (SEMS), external beam radiotherapy, brachytherapy and 
chemotherapy. PDT may be used alone or in combination with any of the above 
therapies though evidence or clinical trials for combination techniques are 
limited. 
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5.2 Current Indications for PDT as a palliative 
oesophageal cancer treatment 
PDT is appropriate for patients with obstructive endo-luminal lesions particularly 
those in the upper (post cricoids and cervical) oesophagus; those crossing the 
gastro-oesophageal junction; recurrence of tumour after resection or radical 
chemoradiotherapy and for tumour ingrowth and/ or overgrowth in stents 
(Figure 9). 
 
Figure 9 Effect of PDT on advanced oesophageal cancer 
   
Pre-PDT      Post- PDT 
 
PDT is generally not suitable for tight fibrotic carcinomas or post radiotherapy 
stricturing tumours due to its own stricturing rate. Other relative 
contraindications are patients with portal hypertension, porphyria or 
hypersensitivity to porphyrins, hepatic impairment and the existence of a 
tracheo-oesophageal fistula (153). 
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5.3 Evidence for PDT benefit as a palliative therapy 
5.3.1 PDT as a monotherapy 
PDT has been shown to improve dysphagia in 85%(164) to 90.8%(223) of patients 
with both obstructing and bleeding oesophageal cancers. Complications included 
stricture formation 2%(164)-4.8%(223), perforation 2%, candidal oesophagitis 2%, 
pleural effusions 4% and photosensitivity 6%(164)-10%(223). There was a 
procedure related mortality of 1.8%(164) and the median survival was between 
4.8 months(164) and 5.9months(223).  
 
A multicentre randomised controlled trial  compared PDT using sodium porfimer 
with thermal laser ablation in 218 patients(165). Although this revealed similar 
dysphagia scores in each group at one month PDT was the safer method resulting 
in fewer perforations and a better objective tumour response compared to 
thermal laser. A further randomised controlled trial  also reported on Nd:YAG 
laser  compared to sodium porfimer PDT and revealed that patients treated with 
PDT had significant improvement in their dysphagia  grade and performance 
status at 4 weeks (p<0.006)compared to the thermal laser group (150). In 
addition duration of response was better in the PDT group but overall survival 
was similar at 145 days for PDT and 128 days for Nd:YAG. Interestingly both 
Lightdale and Heier found that both methods required at least two treatments to 
achieve adequate clinical response (150;165).This is important clinically when 
considering these therapies. 
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5.3.2 PDT as a dual therapy 
5.3.2.1 PDT and radiotherapy 
Several combination therapies have been studied including PDT and 
radiotherapy. PDT produces luminal necrosis of tumour (in effect a form of 
brachytherapy) with radiotherapy affecting loco-regional disease. There is some 
evidence (224;225) that PDT may act as a radiosensitiser although this has not 
been subject to randomised trials. 
 
 Three patients with concurrent PDT/radiotherapy have been  retrospectively 
studied(224). Two oesophageal cancer patients were treated with combined 
chemotherapy and external beam radiation followed by intraluminal 
brachytherapy and then received sodium porfimer PDT for recurrence. A third 
patient with non small cell lung cancer was treated with external beam radiation 
followed by intraluminal brachytherapy and then received PDT for recurrence. 
One oesophageal patient developed a tracheo-oesophageal fistula requiring a 
stent and the other developed quadriplegia due to an epidural abscess arising 
from a fistula within the diseased portion of the oesophagus. The lung cancer 
patient had a massive haemoptysis two days after the PDT and died 2 days later 
– post mortem revealed necrotising arteritis of the right pulmonary artery. This 
suggests that patients having had external beam radiation and brachytherapy are 
high risk for severe complication if recurrence is treated with PDT.  
 
A larger study with more positive results  assessed 15 patients treated with 
external beam radiation, brachytherapy and PDT(225). In this study there was a 
severe complication rate of 5.7% and mortality of 1.9%. This study had a good 
overall survival of 16.8 months and concluded that the use of PDT with 
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irradiation was associated with acceptable survival rate, complication rate and 
reasonable quality of life. This area continues to be explored as the benefit of 
PDT with irradiation is the ability of porfimer sodium to act as a radio sensitizing 
agent (225-227). Clearly further studies are warranted to assess this combination 
therapy. 
 
5.3.2.2 PDT and Stents (SEMS) 
PDT has previously been compared to SEMS in a randomised trial though 
published in abstract format only(228). This revealed that PDT and SEMS 
provided relief of dysphagia but there was a greater early improvement with 
SEMS. Although the re-intervention rate was greater in the PDT group, quality of 
life remained stable compared with the stent group. Survival was similar in both 
groups. 
 
This group's initial experience with PDT was in the palliation of advanced, 
inoperable oesophageal cancer. They had also previously assessed the 
performance of plastic and self expanding metallic stents (SEMS) in the palliation 
of oesophageal cancer in a randomised study of 50 patients(229) this study 
actually demonstrated similar outcomes in terms of quality of life and dysphagia 
scores with SEMS having better survival (107 days compared to 62 days with 
plastic prosthesis) though not statistically significant. 
 It was decided to compare the outcome of patients palliated with PDT with the 
previous historical group having SEMS. A retrospective cost analysis was 
performed as part of this along with evaluation of quality of life and survival in 
these patients having palliative therapy with PDT and SEMS. 
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5.4 Patients  
All patients studied had locally advanced inoperable oesophageal carcinoma with 
or without metastatic disease. This was a pragmatic retrospective review and 
previous treatments e.g. laser or radiotherapy, were not exclusion criteria and 
there were no restrictions in later adjuvant treatment e.g. Chemotherapy. 
Patients were excluded from the study if they had a tracheo-oesophageal fistula. 
 
Two groups of patients were studied. Group 1 (n=25) had photodynamic laser 
therapy (1999 – 2005) with Group 2 (n=25) having metallic stent insertion (1998 – 
2000). Table 7 summarises the demographics for both sets of patients who were 
matched in terms of age, sex, histology, cancer location and stage of disease. 
 
Table 7 Demographics of palliative patients (PDT vs SEMS) 
Demographics 
 
PDT 
(n=25) 
Stent 
(n=25) 
Age - median 
Gender – male 
             - female 
78.9 
16 (64%) 
9 (36%) 
72.9 
17(68%) 
8 (32%) 
Duration of 
symptoms(months)* 
2.8  (0.8)** 5.7  (0.7) 
Length of stricture (cm)* 5.3  (0.6) 8.0  (0.8) 
Distance from incisors (cm)* 28.6  (1.2) 30.4  (0.2) 
Histology 
Squamous cell carcinoma 
Adenocarcinoma 
Other 
Missing 
 
11 (44%) 
13 (52%) 
0    (0%) 
      1    (4%) 
 
13 (52%)                          
 12 (48%) 
 0 (0%) 
Metastatic spread 11 (44%)    16 (64%) 
 
* Mean (SEM) 
** Analysis restricted to the 11 patients reporting symptoms of less than 12 
months 
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5.5 Methods 
5.5.1 Data 
Data on patients receiving a metallic stent had been collected as part of the 
ROSS trial, from 1998 to 2000(229). Data for patients treated with PDT was 
collected retrospectively for 11 patients by conducting a case note review of all 
patients treated with PDT between 1999 and 2003. Data was collected 
prospectively for the remaining 14 patients treated between 2003 and 2005. 
Data collection continued for 9 months after the initial PDT intervention or until 
death, whichever came sooner. 
 
5.5.2 PDT 
Informed consent was given by the patients for the PDT after they had been 
counselled both verbally and with written and visual information as to what the 
treatment involved. Protective clothing in terms of hat, sunglasses and gloves 
were provided for the patients and standard advice given to stay out of direct 
sunlight for the ninety days post procedure. 
Each patient had their treatment as an inpatient. They received intravenous 
Photofrin (porfimer sodium) at 2mg/Kg and then had an endoscopy 48 hours 
later under intravenous sedation using midazolam. A laser light 630nm via a 
5.0cm fibre was passed endoscopically to the level of the tumour and a light 
dose of 300J/cm applied. Patients received high flow oxygen for at least two 
hours pre and post procedure. 
 
5.5.3 SEMS 
This subgroup of patients have previously been described (229). This study was 
approved by the local research ethics committee. Patients gave verbal and 
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written consent for the trial. Patients treated by oesophageal stent insertion 
received either WallstentsTm (Boston Scientific Corp., Watertown, Mass., USA) 
or, in one case, a covered UltraflexTm (Boston Scientific Corp., Watertown, Mass 
USA) stent. These were placed under radiological guidance, as previously 
described(229). 
 
5.6 Outcome Assessments 
5.6.1 Quality of Life 
Quality of life (QoL) was measured using the European Organisation for Research 
and Treatment of Cancer (EORTC) QLQ-C30 questionnaire(230;231) plus an 
oesophageal cancer-specific module (EORTC QLQ-OES 18)(232). This is a 
validated oesophageal cancer specific QoL assessment method. QoL was 
measured pre PDT and 6 weeks post procedure. This questionnaire measured five 
functional scales, physical, emotional, role, cognitive and social function. It also 
looked at general health symptoms and disease specific symptoms (dysphagia, 
eating, reflux, pain, saliva, choking, dry mouth, taste, cough and talking). 
Scores were calculated for each of the scales using the EORTC module scoring 
system. This converted the score to a 1-100 scale. These were compared for 
each functional and symptom scale.  
 
5.6.2 Costing Analysis 
This has previously been described(180).This was based on the cost of the initial 
PDT or stent insertion and subsequent re-interventions. Cost of other inpatient 
stays not directly related to PDT or stent insertion e.g. chemotherapy was not 
included. Costs for both PDT and metallic stent insertion were based on 2003 
cost. 
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5.7 Results 
5.7.1 Quality of Life 
There were 14/25 patients who had data collected prospectively for PDT costing 
who also had quality of life (QoL) information collected. 3 patients were 
excluded, one had incompletely filled in data and the other two died before the 
post PDT data could be collected. This left 11 patients (5M, 6F) with a median 
age 82 years (range 67-83).  
 
 
 
Table 8 EORTC Quality of Life scores for the treatment of advanced oesophageal 
cancer with PDT 
 
 Pre PDT Post PDT 
Physical Function 47 (17-100) 47 (20-80) 
Emotional Function 58 (0-92) 67 (25-92) 
Role Function 50 (17-100) 33 (0-83) 
Cognitive Function 67 (0-100) 50 (0-100) 
Social Function 67 (0-100) 50 (0-67) 
Dysphagia Scale 43 (0-77) 43 (0-67) 
Eating Scale 33 (0-100) 50 (0-100) 
Pain Scale 10 (0-33) 10 (0-57) 
Reflux Scale 17 (0-83) 0 (0-100) 
 
 
Table 8 shows median scores and ranges for functional and symptom components 
of the EORTC quality of life. A high functional score meant a high level of 
functioning. A high symptom score meant more symptoms and worse quality of 
life. There were no statistically significant difference between the scores pre 
and post-PDT in any of the functional or symptom groups at 6 weeks post 
procedure. The trial of SEMS vs plastic prosthesis also showed no statistically 
difference in quality of life(229). 
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 Patients with PDT had a greater number of re-interventions (20 patients 
required 50 re-intervention episodes) compared to the SEM group (10 patients 
required 23 episodes) table 9. In both groups dysphagia was the commonest 
indication for re-intervention. The fact that there was no change in quality of 
life pre and post-PDT should be viewed as a positive observation as the natural 
progression of oesophageal cancer usually brings about a rapid deterioration in 
quality of life. 
 
 
Table 9 Re-Interventions Undertaken in patients palliated with PDT and SEMS 
 
Treatment Interventions  
 PDT Stents 
PDT 7 0 
Dilatation 16 0 
Laser 14 9 
Radiotherapy 1 0 
Metallic stent 8 8 
Other 0 6 
Missing 4 0 
 
 
5.7.2 Survival  
Median survival for patients with advanced cancer palliated with PDT was 4.4 
months (range 2.3 - 8.2 months) compared to a median survival for patients 
having SEMS being 3.4 (1- 5.7 months). This suggests that treatment with PDT 
may be associated with an increased length of survival though not statistically 
significant (Graph 5). 
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Graph 5 Survival in patients with advanced oesophageal cancer treated with PDT 
or SEMS 
 
 
5.7.3 Cost 
The total cost of treatment with PDT was higher than with stent palliation. 
There was no significant difference in the mean length of stay or costs of that 
stay for the initial PDT or SEM. The primary cost of Photofrin was greater than 
the cost of a metallic stent. This meant the total cost of treatment in PDT 
patients was higher (PDT mean total costs £4079.43 vs stent mean costs 
£2622.16; cost difference £1457.26 (95% CI: £818.15 - £2096.38). However when 
cost was evaluated on a cost per day survival, PDT cost became similar to the 
cost of SEMS due to the increase in survival in the patients treated with PDT. 
 
5.8 Discussion 
There are very few randomised trials comparing PDT to other palliative methods 
(165;228) and as yet the optimal palliation technique has not been established. 
Most patients are currently treated with a multimodal approach to palliating 
their symptoms. PDT certainly seems safe and effective in improving dysphagia 
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symptoms (164;223), with no detrimental effect on quality of life(180) and this 
group of patients suggests there is an increased length of survival. 
The quality of life data here is limited, in terms of numbers of patients and 
length of time post procedure the data has been recorded (six weeks), however 
this patient population has a natural low survival rate. This is clearly the most 
important parameter to study in evaluating palliative oesophageal cancer 
methods and further studies are warranted. Continuing the QoL recording every 
6 weeks (some of these patients are surviving 4, 5 even 6 months post 
procedure) would give useful information as to whether the QoL seen at 6 weeks 
is maintained. 
 
The increase in survival may be due to study design in comparing retrospective 
and prospective data. It may be because the demographics would suggest that 
the SEMS group were slightly more advanced in terms of disease stage with 
longer strictures, greater length of time with symptoms and increased number of 
patients with metastatic disease. However other studies have shown improved 
survival with the use of PDT for the treatment of cholangiocarcinoma (233-236). 
These studies may therefore suggest increased survival with PDT compared to 
other therapies. The mechanism of increased survival remains unknown but PDT 
could induce either a systemic inflammatory response or modulate the immune 
system to improve survival in patients with advanced inoperable oesophageal 
cancer.  
 
PDT is perceived to be an expensive treatment due to drug and laser costs as 
well as length of stay for the procedure. It also has a high re-intervention rate 
whether due to the requirement for further PDT or alternative palliative 
methods such as SEMS or laser. However, the documented improved survival is 
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clearly important in bringing the cost down when results are expressed as cost 
per day survival.  
The aim of palliation is primarily symptom control but if we can both improve 
quality and quantity of survival time left for these advanced cancer patients 
then PDT may be an optimal treatment. 
 
5.9 Conclusion 
PDT remains a promising palliative modality with improved symptom control, no 
reduction in quality of life and increased survival.
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6 Does Photodynamic Therapy Stimulate a 
Systemic Inflammatory Response? 
6.1 Introduction 
There is a complex relationship between inflammation and cancer. Inflammation 
can promote carcinogenesis such as in chronic inflammatory conditions whereby 
the production of growth factors and angiogenic factors which stimulate tissue 
repair can also promote cancer cell survival, implantation and growth(237;238). 
Inflammation can also have an anti-tumour effect by the stimulation of the 
acute inflammatory response which favours activation of the immune effector 
mechanism capable of inducing spontaneous(239-241) or treatment induced 
cancer regression(238;242;243). 
 
Systemic inflammation measured as an elevated C reactive protein (CRP) has 
already been shown to predict poor cancer specific survival in patients 
undergoing resection for gastroesophageal cancer(244;245)and in patients with 
peri-hilar cholangiocarcinoma(246).An elevated CRP level is also a poor 
prognostic factor in advanced oesophageal carcinoma independent of stage(247) 
and elevated serum CRP levels in patients correlate more frequently to non 
responders of chemoradiotherapy(248).CRP is an acute phase protein that may 
become elevated with injury, infection and neoplasia. CRP production is up-
regulated by cytokines such as interleukin-8 (IL-8), interleukin-6 (IL-6) and 
tumour necrosis factor α (TNFα)(249).The exact mechanism whereby the 
systemic inflammatory response syndrome (SIRS) affects cancer outcome remains 
unclear but may be due to impairment of the T lymphocytic response(250;251), 
induction of lymphocytopenia(244) or production of a pro-angiogenic 
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(252)environment allowing rapid tumour growth. The systemic inflammatory 
response (SIR) may also produce micro-necrosis creating an environment with 
abnormal regulation of genes, cell death and mutagenesis(237). The production 
of a systemic inflammatory response may therefore be a detrimental effect of a 
cancer therapy. 
 
PDT produces a photo-oxidation reaction causing direct cell death and induces 
ischaemia in the treated tissue. Several pre-clinical studies(128;129) and one 
clinical study(130) have shown that PDT enhances the host anti-tumour immune 
response. Studies have also shown PDT enhances tumour cell immunogenicity 
and therefore the direct tumour effects of PDT may play an important role in 
enhancing the host anti-tumour immune response(134). PDT can modulate the 
expression of IL-6 and IL-10 in tumour and normal tissues in vivo (132). Damage 
to tumour plasma cell membrane by the photosensitiser initiates processes 
involving the signal transduction pathways. This produces enhanced expression 
of stress proteins and early response genes(253), genes that regulate apoptotic 
cell death(254) and up-regulation of cytokine genes. These stress proteins also 
have a role in antigen presentation and cell adhesion allowing development of a 
PDT induced inflammatory and/or immune response(128). 
 
Photo-oxidative reaction of cell membrane lipids induces activation of 
membranous phospholipases(254)leading to rapid  phospholipid degradation with 
release of lipid fragments and metabolites of arachadonic acid(255;256) which 
are powerful inflammatory mediators. This intense inflammatory reaction which 
is central to the mechanism of PDT mediated tumour destruction, is preceded by 
the release of a wide variety of inflammatory mediators. This includes 
vasoactive substances, components of the complement and coagulation cascade, 
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acute phase proteins, proteinases, peroxidases, radicals, leukocyte chemo-
attractants, cytokines and growth factors(256;257). There is also evidence that 
PDT up-regulates IL- 1β, IL-2, tumour necrosis factor α (TNF-α) and granulocyte 
colony stimulating factor (258-260). 
 
 Photofrin is taken up in large amounts by tumour associated macrophages 
thereby these macrophages play an important role in selective photosensitiser 
uptake by tumour cells (261;262).  After PDT has initiated the inflammatory 
mediators there is a massive invasion of neutrophils, mast cells and 
monocytes/macrophages which has been documented in rodent tumour 
models(132). These cells cause PDT mediated destruction of cancerous tissue 
through immune activation and local anti-tumour immunity.  
 
Several studies have indicated that PDT also has a systemic effect with induction 
of acute phase proteins(263;264),systemic neutrophilia(263;265) increased 
circulating complement proteins(265) and systemic release of pro-inflammatory 
cytokines(259;264), indicating a systemic inflammatory response (SIR). Clinical 
studies on subcutaneous tumours in mice with lung metastases have shown that 
treatment of the skin tumour with PDT leads to regression of the untreated lung 
tumour(266). In this case PDT generates effective and persistent CD8+ T cell 
mediated immune memory response in the absence of CD4+ T cells and that 
natural killer (NK) cells are required for the T cell dependent control of distant 
tumour(266).The effect of PDT therefore may be substantially mediated through 
activation of the immune system. 
 
 In randomised controlled trials of cholangiocarcinoma patients treated with PDT 
compared to stenting, there was an unexpected significant increase in survival 
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time in the PDT group even when matched for age and stage of disease (233-
236).In our own set of patients palliated with PDT, there was a similar increased 
length of survival compared to patients palliated with a self expanding metallic 
stent. It could be postulated that as PDT up regulates cytokine production such 
as IL-6 and TNF-α then the concentration of acute phase proteins such as CRP 
increases bringing about a systemic inflammatory response which may help 
explain the increased length of time of survival. The beneficial effects of PDT on 
tumour related survival may correlate to an activation of local and systemic 
immune modulation and /or enhanced acute local and systemic inflammatory 
response. 
 
To attempt to study tumour modulation effects two hypotheses are postulated 
and require study:  
1. Those patients with a normal CRP pre PDT should have a greater length of 
survival than those with an elevated CRP. 
2. There may be an increased length of survival in patients with an increased 
inflammatory response reflected in percentage rise in CRP. 
 
6.2 Patients and Methods 
Patients who were treated with PDT for early oesophageal cancer were 
retrospectively assessed to investigate whether they had a systemic response 
elicited reflected in a rise in C-Reactive Protein (CRP). 
 
Routine pre-operative laboratory measurements of CRP were carried out on the 
day of admission or anytime up to light activation. The co-efficient of variation 
for these methods was less than 10% established by routine quality control 
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measures. The limit of detection by the assay was 6mgl-1.The post CRP value was 
the highest reached at least 24hours post procedure and up to 72 hours post 
procedure. A CRP level of greater than 10mgl-1 has previously been shown to 
indicate a systemic inflammatory response(267). 
 
There were 38 early cancer patients and 17 had 19 CRP results (two had had a 
second course of PDT). There were 12 males of median age 75 years (range 52-
87), 12 patients had adenocarcinoma, the other 5 squamous cell carcinoma. 
 
To assess response to PDT complete endoscopic and histological response was 
used as an overall indicator of effect. In addition overall survival was also used 
as an outcome parameter. 
 
6.3 Results 
6.3.1 CRP 
The patients median initial CRP value was 6mg/l (range 1 to 41). There was a 
significant rise in CRP levels post- procedure p<0.0001 (Wilcoxon signed rank 
test) (Graph 6). All patients except for one had an increase in CRP post 
procedure. Seven initial CRP levels were greater than or equal to 10mg/l. 
Overall this represented a median rise in CRP of 466% as an acute response to 
PDT. 
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Graph 6 
 
 
6.3.2 Survival 
In this small group of patients there were an increased length of survival in days 
between patients with a pre-treatment CRP<10mg/l compared to a CRP≥10mg/l 
(Graph 7).This is statistically significant p=0.05 (Spearman’s rank correlation 
coefficient).There was no correlation between the percentage rise in CRP and 
overall survival (graph 8). 
 
 
 
 
 
 p=0.0001  
(Wilcoxon signed 
rank test) 
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Graph 7 Patients with a pre-treatment CRP< 10mg/l have increased length of 
survival 
 
 
 
Graph 8 Correlation between percentage rise in CRP and survival 
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6.4 Discussion 
In this small number of patients, all but one had a significant rise in CRP post 
PDT treatment. This could be explained as the normal inflammatory response to 
surgery noted in patients undergoing a wide variety of surgical procedures which 
generally peaks on day 3 and falls thereafter(268). It could also represent a 
systemic inflammatory response to the activated intravenous sodium porfimer 
allowing treatment of micro-metastases elsewhere ultimately leading to 
increased survival.  
 
These CRP levels were collected retrospectively and had been checked during 
their inpatient stay. It would be interesting to prospectively evaluate CRP levels 
and record them a week after treatment to determine whether the rise in CRP is 
prolonged and its duration. If there is a sustained rise in CRP then this would 
suggest an ongoing inflammatory response perhaps secondary to activation of 
inflammatory mediators by PDT. This theory could be supported by assessing 
other inflammatory mediators which may play a role such as IL6, IL10 and TNF-α. 
 
There was no correlation between baseline CRP and response to treatment. It is 
more likely that response to treatment is dependent on tumour biology, 
photosensitiser type and light dosimetry rather than baseline inflammatory 
response. 
 
 It is interesting that there was a statistically significant increased length of 
survival when a patient’s pre-treatment CRP is <10mg/l. The threshold of 
≥10mg/l was used as this has previously been described as being an independent 
Chapter 6  105 
predictor of poor cancer specific survival(244) in patients with operable gastro-
oesophageal cancer. Although this cohort of patients was technically operable 
they did not have surgery due to their co-morbidity. The pre-treatment CRP 
could therefore be part of the staging process providing supportive evidence for 
endoscopic treatment rather than major resection in patients with borderline 
fitness for surgery. 
 
Graph 9 Does percentage rise in CRP affect response to treatment? 
 
There is some evidence in this small cohort of patients that an increased CRP 
rise post-treatment is more likely to be associated with  a poor response (Graph 
9). This may suggest that a large inflammatory response has a detrimental effect 
on the patients’ response to treatment. However CRP is produced in response to 
a whole range of inflammatory mediators. It may be particular mediators such as 
IL6 or IL8 or anti TNF-α which are produced more in non-responder patients, 
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hence higher increase in CRP. PDT also stimulates CD8+ T cells(266), neutrophils 
and activates adrenal hormone production(265) as part of the acute phase 
response. These levels would need to be evaluated in PDT patients and related 
to survival before one could truly say the very high inflammatory response 
brought about a lack of response to treatment.  
 
There was no clear relationship between post-treatment CRP rises and other 
treatment response or survival. However there was a definite trend towards a 
negative correlation between CRP rise and survival (Graph 8) suggesting that a 
large SIR may indeed be a detrimental response. Further evaluation of this would 
require prospective study with significantly greater patient numbers. 
 
6.5 Conclusion 
There is definite evidence that PDT stimulates a systemic inflammatory response 
measured by a percentage rise in CRP post treatment. Further work is needed to 
investigate whether this inflammatory response is sustained past three days and 
which local and systemic inflammatory mediators and cells are involved and 
whether it affects overall survival. 
A high pre-treatment CRP level ≥ 10mg/l is associated with a reduced length of 
survival. This may be of value during MDT discussion about treatment options in 
these patients. 
It may be concluded that on present evidence any systemic effect of PDT is not 
mediated through a SIR and may therefore be related to an immune based 
effect. Further studies on PDT immune modulation would therefore seem 
warranted.
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7 Future Directions of PDT 
 
Photodynamic therapy has been shown to be a safe and effective treatment for 
early oesophageal cancer (142;174;199;269) and the palliation of advanced 
oesophageal cancer (163-165;223;225;228). With the incidence of oesophageal 
adenocarcinoma continuing to rise(8) in the western world and with Scotland in 
particular having the highest incidence of oesophageal adenocarcinoma in 
Europe(6;7) then it is important to continue to strive to find therapies to treat  
pre malignant and malignant disease of the oesophagus for those patients 
diagnosed in currently running surveillance programmes. There also continues to 
be a proportion of patients in whom surgical resection or chemoradiotherapy is 
not an option due to medical co-morbidity or poor performance status so 
endoscopic therapy offers an alternative potentially curative treatment. With 
only 20-30% of patients being staged as potentially curative (270) at the time of 
diagnosis it is important to establish the optimal palliative technique for 
dysphagia(222). 
 
As previously discussed Barrett’s oesophagus is a pre malignant condition of the 
oesophagus in which high grade dysplasia and oesophageal adenocarcinoma may 
develop with an annual neoplastic transformation rate of 0.12%(204) to 
0.5%(39).The gold standard treatment for Barrett’s HGD is still surgical resection 
but in elderly patients or those with multiple co-morbidity or those with poor 
performance status endoscopic therapy is a real alternative. 
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A recent landmark consensus paper has concluded that endoscopic ablative 
therapy should be regarded as primary treatment option in HGD and early 
oesophageal cancer (271). In the group of patients treated with PDT studied in 
this thesis, the eradication of HGD was 85% with a 15% cancer progression rate at 
5 years. This is similar to previous studies(199).Patients who developed 
recurrence along the way were successfully treated with repeat PDT or 
radiofrequency ablation(RFA). 
 
The current optimal endoscopic therapy is RFA, with a cancer progression rate of 
2.4% (272)and 90% of patients have no HGD after therapy(273).RFA also has the 
ability to remove the entire Barrett’s segment with a reduced stricturing rate 
and maintenance of normal oesophageal compliance(274) and many see this as a 
better endoscopic therapy(271).  In addition follow up after RFA suggests this 
technique is durable with high (>90%) ablation rates up to 3 years (92). However 
there is as yet no randomised controlled trial comparing the two therapies and 
longer term data for HGD treated with RFA is currently awaited.  
 
PDT remains an effective treatment and will continue to have a role in HGD in 
Barrett’s oesophagus as either primary treatment in those patients not suitable 
for surgical resection or in those patients who have failed RFA. 
 
7.1 Future Developments in PDT 
Development of PDT into an optimal therapy would involve more targeted 
mucosal ablation with avoidance of deeper tissue penetration thereby reducing 
stricture rates. It would also be helpful to decrease the length of 
photosensitivity post treatment. Also of primary importance however would be 
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the ability to alter the depth of tissue necrosis dependent on the stage of 
disease. Along with the treatment of long segments of Barrett’s oesophagus, 
these modifications would make this a “perfect” treatment option. 
 
Development of different photosensitisers which have different depths of 
penetration and so could be used for different types of disease would be a 
further advance for PDT. This could allow a particular photosensitiser to 
concentrate in mucosal tissue to specifically treat mucosal disease or another 
photosensitiser concentrated in the sub mucosa to allow treatment of early 
cancer. More advanced disease would require even deeper penetration involving 
the muscularis propria. 
The alternative way to modify PDT would be by alteration of light dosimetry as 
this would also alter depth of tissue penetration(150). By altering the type of 
photosensitiser or the light dosimetry delivered then the risk of the major severe 
stricturing (158;169) post oesophageal PDT may decrease. Ideally the 
photosensitiser would also have a short half life so the length of photosensitivity 
would be reduced and this in turn would improve quality of life post procedure 
whatever the indication. 
 
7.2 PDT development in the treatment of Barrett's HGD 
This group of HGD patients all had a decreased length of Barrett’s segment 
(Graph 2) post treatment but PDT did not remove Barrett’s altogether. This may 
be because it was targeted not to treat the whole Barrett’s segment but rather 
the area of histologically confirmed HGD only primarily because of the concern 
regarding strictures. Theoretically this means non dysplastic Barrett’s 
oesophagus but with malignant potential was left(87;206;275), although in this 
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group of patients, recurrence and cancer only occurred in the initial treated 
area with HGD. If the way in which delivery of the laser light was altered, 
perhaps by a long cylindrical delivery system, then the whole length of the 
Barrett’s segment could be treated and this would improve the overall 
treatment. Again with improved photosensitisers and light dosimetry then using 
PDT along a whole Barrett’s segment would be feasible and may not induce 
stricture formation. Potentially such a treatment would have safety advantages 
over thermal contact devices such as RFA although major developments in the 
photosensitiser field would be required. 
 
7.3 PDT developments in early cancer 
PDT is also an effective treatment for early oesophageal cancer(70). In this 
group of patients who were deemed unfit for radical treatment due to medical 
co-morbidity PDT was given with curative intent. Endoscopic ultrasound (EUS) 
successfully predicted T2/T3 cancers which were clearly not responsive to 
treatment by PDT. Although EUS staged true early T1 cancers, not all of these 
responded to treatment. It is now clear that EUS only has a limited role in 
staging early (69;71) cancers and endoscopic therapy has now moved to using 
EMR for both staging (63)and primary treatment(84;85). Further randomised 
studies should consider EMR and PDT vs EMR and RFA in the treatment of such 
early cancers. 
 
Sixty eight percent of patients had a complete endoscopic and histological 
response to PDT. However 65% developed recurrence of either HGD or carcinoma 
at a median of 241 days, of which 40% of them were cleared with further PDT. 
Treatment with PDT did not prevent any patient who did not respond or who 
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recurred having other forms of treatment including surgery (which was not 
technically more demanding due to the previous PDT treatment). Initial non 
responders did not respond to further courses of treatment. It is interesting that 
some T1N0 patients failed to respond completely. The reason for this remains 
unclear, but investigation of the tumour biology of these particular patients 
compared to responders may be of value. In addition evaluation of tumour 
biomarkers which could predict response may also be of interest(276). This 
biomarker information could then be established from the initial diagnostic 
biopsies so treatment could be tailored accordingly. 
 
7.4 PDT developments in oesophageal cancer palliation 
The optimal palliative technique for oesophageal cancer has not yet been 
established. Trials comparing PDT and laser(165) have shown PDT to be  at least 
equal and better in terms of tumour response although trials comparing PDT and 
SEMS(228) have shown superiority in terms of cost and dysphagia scores but not 
quality of life for patients with SEMS. No trial has compared the three. In this 
group of patients compared to SEMS, neither was superior in symptoms control 
but PDT definitely appears to show a survival benefit(228). There may be several 
reasons for this: SEMS patients tended to have slightly more advanced disease, 
PDT patients had more intervention rates – this translated to more frequent 
hospital interventions and review by specialist medical and nursing staff and 
hence issues such as nutrition and symptom control were perhaps better 
addressed. It is likely that a randomised controlled trial comparing laser, SEMS 
and PDT in age and stage matched patients is the only way forward here with 
important endpoints being dysphagia, survival, cost per day survival and quality 
of life in particular.  
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As palliative intent accounts for 80% of patients(270) any improvements in 
quality of life and survival would be of immense healthcare benefit. 
 
Further studies into how PDT may improve survival are required particularly to 
evaluate the role of the inflammatory or immune response in tumour modulation 
(239-241). If the apparent improved survival with PDT is confirmed (233-236), 
understanding the underlying mechanisms, may allow augmentation of PDT with 
other agents.  
 
The role of the inflammatory response could be further assessed by evaluating 
inflammatory mediators in tissue biopsies and blood pre and immediately post- 
PDT light activation and several weeks after PDT treatment. The ability of PDT 
to augment natural immunity leading to cancer cure would be of massive 
importance. 
 
7.5 Summary 
This thesis has explored the history and development of PDT in the field of 
oesophageal pre, early and advanced neoplasia. It has been shown that this is a 
safe and effective treatment for Barrett’s HGD, early oesophageal cancer and 
certainly has a role to play in the palliation of advanced disease. The future 
remains exciting as this endoscopic ablative therapy develops further. 
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